{"entity":"abbvie","name":"AbbVie","kind":"money","summary":"AbbVie's timeline holds 394 money & deals claims from 2010 to 2026. The latest took effect on October 26, 2026.","counts":{"total":404,"by_kind":{"people":2,"money":394,"products":0,"models":0,"other":8}},"events":[{"date":"2010-12-31","until":"2011-12-31","published":"2014-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 10,000,000 United States dollar\", as of 2010-12-31 (until 2011-12-31). Claim clm_A4E25B7E8BD9, https://asof.is/claim/clm_A4E25B7E8BD9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746914001154/0001047469-14-001154-index.htm.","url":"https://asof.is/claim/clm_A4E25B7E8BD9","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"10,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A4E25B7E8BD9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2013, filed 2014-02-21"}},{"date":"2011-12-31","until":"2012-12-31","published":"2014-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie operating income: 3,620,000,000 United States dollar\", as of 2011-12-31 (until 2012-12-31). Claim clm_3C7DE622672F, https://asof.is/claim/clm_3C7DE622672F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746914001154/0001047469-14-001154-index.htm.","url":"https://asof.is/claim/clm_3C7DE622672F","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"3,620,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3C7DE622672F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2013, filed 2014-02-21"}},{"date":"2011-12-31","until":"2012-03-31","published":"2014-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 27,000,000 United States dollar\", as of 2011-12-31 (until 2012-03-31). Claim clm_5C2DFBA489B1, https://asof.is/claim/clm_5C2DFBA489B1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746914001154/0001047469-14-001154-index.htm.","url":"https://asof.is/claim/clm_5C2DFBA489B1","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"27,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5C2DFBA489B1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2013, filed 2014-02-21"}},{"date":"2011-12-31","until":"2012-12-31","published":"2014-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie revenue: 17,444,000,000 United States dollar\", as of 2011-12-31 (until 2012-12-31). Claim clm_A43C77B35651, https://asof.is/claim/clm_A43C77B35651, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746914001154/0001047469-14-001154-index.htm.","url":"https://asof.is/claim/clm_A43C77B35651","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"17,444,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A43C77B35651","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-K FY2013, filed 2014-02-21"}},{"date":"2012-03-31","until":"2012-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 978,000,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_495312E370FA, https://asof.is/claim/clm_495312E370FA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465913038917/0001104659-13-038917-index.htm.","url":"https://asof.is/claim/clm_495312E370FA","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"978,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_495312E370FA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2013, filed 2013-05-08"}},{"date":"2012-03-31","until":"2012-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 41,000,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_6BE76CD99628, https://asof.is/claim/clm_6BE76CD99628, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465913038917/0001104659-13-038917-index.htm.","url":"https://asof.is/claim/clm_6BE76CD99628","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"41,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6BE76CD99628","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2013, filed 2013-05-08"}},{"date":"2012-03-31","until":"2012-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 4,173,000,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_F93636EB7531, https://asof.is/claim/clm_F93636EB7531, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465913038917/0001104659-13-038917-index.htm.","url":"https://asof.is/claim/clm_F93636EB7531","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"4,173,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F93636EB7531","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q1 FY2013, filed 2013-05-08"}},{"date":"2012-06-30","until":"2012-09-30","published":"2013-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 1,422,000,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_0C8082C36A8A, https://asof.is/claim/clm_0C8082C36A8A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465913062262/0001104659-13-062262-index.htm.","url":"https://asof.is/claim/clm_0C8082C36A8A","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,422,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0C8082C36A8A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2013, filed 2013-08-09"}},{"date":"2012-06-30","until":"2012-09-30","published":"2013-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 74,000,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_8AB294800E36, https://asof.is/claim/clm_8AB294800E36, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465913062262/0001104659-13-062262-index.htm.","url":"https://asof.is/claim/clm_8AB294800E36","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"74,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8AB294800E36","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2013, filed 2013-08-09"}},{"date":"2012-06-30","until":"2012-09-30","published":"2013-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 4,493,000,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_FEDE06BBE100, https://asof.is/claim/clm_FEDE06BBE100, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465913062262/0001104659-13-062262-index.htm.","url":"https://asof.is/claim/clm_FEDE06BBE100","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"4,493,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FEDE06BBE100","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q2 FY2013, filed 2013-08-09"}},{"date":"2012-09-30","until":"2012-12-31","published":"2013-11-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 2,761,000,000 United States dollar\", as of 2012-09-30 (until 2012-12-31). Claim clm_21E51F4C56F5, https://asof.is/claim/clm_21E51F4C56F5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465913083686/0001104659-13-083686-index.htm.","url":"https://asof.is/claim/clm_21E51F4C56F5","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"2,761,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_21E51F4C56F5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2013, filed 2013-11-12"}},{"date":"2012-09-30","until":"2013-03-31","published":"2013-11-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 4,508,000,000 United States dollar\", as of 2012-09-30 (until 2013-03-31). Claim clm_B5C99B331875, https://asof.is/claim/clm_B5C99B331875, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465913083686/0001104659-13-083686-index.htm.","url":"https://asof.is/claim/clm_B5C99B331875","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"4,508,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B5C99B331875","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q3 FY2013, filed 2013-11-12"}},{"date":"2012-09-30","until":"2013-03-31","published":"2013-11-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 1,596,000,000 United States dollar\", as of 2012-09-30 (until 2013-03-31). Claim clm_BC38E2A501A2, https://asof.is/claim/clm_BC38E2A501A2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465913083686/0001104659-13-083686-index.htm.","url":"https://asof.is/claim/clm_BC38E2A501A2","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,596,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BC38E2A501A2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2013, filed 2013-11-12"}},{"date":"2012-12-31","until":"2013-12-31","published":"2014-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie operating income: 5,817,000,000 United States dollar\", as of 2012-12-31 (until 2013-12-31). Claim clm_2E2748C2CF51, https://asof.is/claim/clm_2E2748C2CF51, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746914001154/0001047469-14-001154-index.htm.","url":"https://asof.is/claim/clm_2E2748C2CF51","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"5,817,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2E2748C2CF51","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2013, filed 2014-02-21"}},{"date":"2012-12-31","until":"2013-03-31","published":"2014-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: -350,000,000 United States dollar\", as of 2012-12-31 (until 2013-03-31). Claim clm_3D3AD133EF58, https://asof.is/claim/clm_3D3AD133EF58, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746914001154/0001047469-14-001154-index.htm.","url":"https://asof.is/claim/clm_3D3AD133EF58","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"-350,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3D3AD133EF58","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2013, filed 2014-02-21"}},{"date":"2012-12-31","until":"2013-12-31","published":"2014-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie revenue: 18,380,000,000 United States dollar\", as of 2012-12-31 (until 2013-12-31). Claim clm_7D34A43B5B1E, https://asof.is/claim/clm_7D34A43B5B1E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746914001154/0001047469-14-001154-index.htm.","url":"https://asof.is/claim/clm_7D34A43B5B1E","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"18,380,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7D34A43B5B1E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-K FY2013, filed 2014-02-21"}},{"date":"2012-12-31","until":"2013-03-31","published":"2014-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 27,008,000,000 United States dollar\", as of 2012-12-31 (until 2013-03-31). Claim clm_8F8F210CA067, https://asof.is/claim/clm_8F8F210CA067, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746914001154/0001047469-14-001154-index.htm.","url":"https://asof.is/claim/clm_8F8F210CA067","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"27,008,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8F8F210CA067","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2013, filed 2014-02-21"}},{"date":"2012-12-31","until":"2013-03-31","published":"2014-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 5,901,000,000 United States dollar\", as of 2012-12-31 (until 2013-03-31). Claim clm_D328E96523A5, https://asof.is/claim/clm_D328E96523A5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746914001154/0001047469-14-001154-index.htm.","url":"https://asof.is/claim/clm_D328E96523A5","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"5,901,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D328E96523A5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2013, filed 2014-02-21"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 6,979,000,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_06BF7AB6F5F9, https://asof.is/claim/clm_06BF7AB6F5F9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465913038917/0001104659-13-038917-index.htm.","url":"https://asof.is/claim/clm_06BF7AB6F5F9","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"6,979,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_06BF7AB6F5F9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2013, filed 2013-05-08"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 2,957,000,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_30E9608F5809, https://asof.is/claim/clm_30E9608F5809, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465913038917/0001104659-13-038917-index.htm.","url":"https://asof.is/claim/clm_30E9608F5809","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"2,957,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_30E9608F5809","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2013, filed 2013-05-08"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 1,305,000,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_69DD4A7597DD, https://asof.is/claim/clm_69DD4A7597DD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465913038917/0001104659-13-038917-index.htm.","url":"https://asof.is/claim/clm_69DD4A7597DD","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,305,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_69DD4A7597DD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2013, filed 2013-05-08"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 4,329,000,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_8FCC99AEFBF3, https://asof.is/claim/clm_8FCC99AEFBF3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465913038917/0001104659-13-038917-index.htm.","url":"https://asof.is/claim/clm_8FCC99AEFBF3","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"4,329,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8FCC99AEFBF3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q1 FY2013, filed 2013-05-08"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 27,169,000,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_BF8527D581D8, https://asof.is/claim/clm_BF8527D581D8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465913038917/0001104659-13-038917-index.htm.","url":"https://asof.is/claim/clm_BF8527D581D8","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"27,169,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BF8527D581D8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2013, filed 2013-05-08"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,583,729,114 shares\", as of 2013-03-31 (until 2013-06-30). Claim clm_CFC2CCBD26FA, https://asof.is/claim/clm_CFC2CCBD26FA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465913038917/0001104659-13-038917-index.htm.","url":"https://asof.is/claim/clm_CFC2CCBD26FA","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,583,729,114 shares","status":"superseded","assertable":true,"id":"clm_CFC2CCBD26FA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2013, filed 2013-05-08"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 8,743,000,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_2DEB42070657, https://asof.is/claim/clm_2DEB42070657, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465913062262/0001104659-13-062262-index.htm.","url":"https://asof.is/claim/clm_2DEB42070657","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"8,743,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2DEB42070657","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2013, filed 2013-08-09"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 3,558,000,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_4A958341B1C9, https://asof.is/claim/clm_4A958341B1C9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465913062262/0001104659-13-062262-index.htm.","url":"https://asof.is/claim/clm_4A958341B1C9","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"3,558,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4A958341B1C9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2013, filed 2013-08-09"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 27,910,000,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_81724D6111B8, https://asof.is/claim/clm_81724D6111B8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465913062262/0001104659-13-062262-index.htm.","url":"https://asof.is/claim/clm_81724D6111B8","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"27,910,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_81724D6111B8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2013, filed 2013-08-09"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 4,692,000,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_9BDF5524D4D8, https://asof.is/claim/clm_9BDF5524D4D8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465913062262/0001104659-13-062262-index.htm.","url":"https://asof.is/claim/clm_9BDF5524D4D8","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"4,692,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9BDF5524D4D8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q2 FY2013, filed 2013-08-09"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 1,453,000,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_ABFEE686F09F, https://asof.is/claim/clm_ABFEE686F09F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465913062262/0001104659-13-062262-index.htm.","url":"https://asof.is/claim/clm_ABFEE686F09F","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,453,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_ABFEE686F09F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2013, filed 2013-08-09"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,585,428,724 shares\", as of 2013-06-30 (until 2013-09-30). Claim clm_AC2DD135BFA3, https://asof.is/claim/clm_AC2DD135BFA3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465913062262/0001104659-13-062262-index.htm.","url":"https://asof.is/claim/clm_AC2DD135BFA3","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,585,428,724 shares","status":"superseded","assertable":true,"id":"clm_AC2DD135BFA3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2013, filed 2013-08-09"}},{"date":"2013-09-30","until":"2013-12-31","published":"2013-11-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 8,975,000,000 United States dollar\", as of 2013-09-30 (until 2013-12-31). Claim clm_3AE3F00A4472, https://asof.is/claim/clm_3AE3F00A4472, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465913083686/0001104659-13-083686-index.htm.","url":"https://asof.is/claim/clm_3AE3F00A4472","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"8,975,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3AE3F00A4472","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2013, filed 2013-11-12"}},{"date":"2013-09-30","until":"2014-03-31","published":"2013-11-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 1,371,000,000 United States dollar\", as of 2013-09-30 (until 2014-03-31). Claim clm_852AC8B3FCCC, https://asof.is/claim/clm_852AC8B3FCCC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465913083686/0001104659-13-083686-index.htm.","url":"https://asof.is/claim/clm_852AC8B3FCCC","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,371,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_852AC8B3FCCC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2013, filed 2013-11-12"}},{"date":"2013-09-30","until":"2014-03-31","published":"2013-11-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 4,658,000,000 United States dollar\", as of 2013-09-30 (until 2014-03-31). Claim clm_A061D1ED53C1, https://asof.is/claim/clm_A061D1ED53C1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465913083686/0001104659-13-083686-index.htm.","url":"https://asof.is/claim/clm_A061D1ED53C1","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"4,658,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A061D1ED53C1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q3 FY2013, filed 2013-11-12"}},{"date":"2013-09-30","until":"2014-01-31","published":"2013-11-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,590,861,812 shares\", as of 2013-09-30 (until 2014-01-31). Claim clm_CF64F485A489, https://asof.is/claim/clm_CF64F485A489, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465913083686/0001104659-13-083686-index.htm.","url":"https://asof.is/claim/clm_CF64F485A489","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,590,861,812 shares","status":"superseded","assertable":true,"id":"clm_CF64F485A489","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2013, filed 2013-11-12"}},{"date":"2013-09-30","until":"2013-12-31","published":"2013-11-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 28,252,000,000 United States dollar\", as of 2013-09-30 (until 2013-12-31). Claim clm_D47B65E8AFA3, https://asof.is/claim/clm_D47B65E8AFA3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465913083686/0001104659-13-083686-index.htm.","url":"https://asof.is/claim/clm_D47B65E8AFA3","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"28,252,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D47B65E8AFA3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2013, filed 2013-11-12"}},{"date":"2013-09-30","until":"2013-12-31","published":"2013-11-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 3,577,000,000 United States dollar\", as of 2013-09-30 (until 2013-12-31). Claim clm_DC81000AB742, https://asof.is/claim/clm_DC81000AB742, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465913083686/0001104659-13-083686-index.htm.","url":"https://asof.is/claim/clm_DC81000AB742","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"3,577,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DC81000AB742","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2013, filed 2013-11-12"}},{"date":"2013-12-31","until":"2014-03-31","published":"2014-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 4,492,000,000 United States dollar\", as of 2013-12-31 (until 2014-03-31). Claim clm_0FAC938AA466, https://asof.is/claim/clm_0FAC938AA466, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746914001154/0001047469-14-001154-index.htm.","url":"https://asof.is/claim/clm_0FAC938AA466","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"4,492,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0FAC938AA466","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2013, filed 2014-02-21"}},{"date":"2013-12-31","until":"2014-12-31","published":"2014-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie revenue: 18,790,000,000 United States dollar\", as of 2013-12-31 (until 2014-12-31). Claim clm_10EA1069A66F, https://asof.is/claim/clm_10EA1069A66F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746914001154/0001047469-14-001154-index.htm.","url":"https://asof.is/claim/clm_10EA1069A66F","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"18,790,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_10EA1069A66F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-K FY2013, filed 2014-02-21"}},{"date":"2013-12-31","until":"2014-03-31","published":"2014-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 9,595,000,000 United States dollar\", as of 2013-12-31 (until 2014-03-31). Claim clm_4FA738BFF268, https://asof.is/claim/clm_4FA738BFF268, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746914001154/0001047469-14-001154-index.htm.","url":"https://asof.is/claim/clm_4FA738BFF268","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"9,595,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4FA738BFF268","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2013, filed 2014-02-21"}},{"date":"2013-12-31","until":"2014-03-31","published":"2014-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 29,198,000,000 United States dollar\", as of 2013-12-31 (until 2014-03-31). Claim clm_7B4C916FCBA1, https://asof.is/claim/clm_7B4C916FCBA1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746914001154/0001047469-14-001154-index.htm.","url":"https://asof.is/claim/clm_7B4C916FCBA1","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"29,198,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7B4C916FCBA1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2013, filed 2014-02-21"}},{"date":"2013-12-31","until":"2014-12-31","published":"2014-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie operating income: 5,664,000,000 United States dollar\", as of 2013-12-31 (until 2014-12-31). Claim clm_A9B273E426B3, https://asof.is/claim/clm_A9B273E426B3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746914001154/0001047469-14-001154-index.htm.","url":"https://asof.is/claim/clm_A9B273E426B3","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"5,664,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A9B273E426B3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2013, filed 2014-02-21"}},{"date":"2014-01-31","until":"2014-03-31","published":"2014-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,588,518,764 shares\", as of 2014-01-31 (until 2014-03-31). Claim clm_C2C5ABA39CC8, https://asof.is/claim/clm_C2C5ABA39CC8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746914001154/0001047469-14-001154-index.htm.","url":"https://asof.is/claim/clm_C2C5ABA39CC8","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,588,518,764 shares","status":"superseded","assertable":true,"id":"clm_C2C5ABA39CC8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2013, filed 2014-02-21"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 8,140,000,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_02534370C6B0, https://asof.is/claim/clm_02534370C6B0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465914036968/0001104659-14-036968-index.htm.","url":"https://asof.is/claim/clm_02534370C6B0","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"8,140,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_02534370C6B0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2014, filed 2014-05-09"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 4,697,000,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_18424292F5EF, https://asof.is/claim/clm_18424292F5EF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465914036968/0001104659-14-036968-index.htm.","url":"https://asof.is/claim/clm_18424292F5EF","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"4,697,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_18424292F5EF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2014, filed 2014-05-09"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 4,563,000,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_3B799E473A52, https://asof.is/claim/clm_3B799E473A52, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465914036968/0001104659-14-036968-index.htm.","url":"https://asof.is/claim/clm_3B799E473A52","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"4,563,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3B799E473A52","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q1 FY2014, filed 2014-05-09"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 1,351,000,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_781C2FB5DFBA, https://asof.is/claim/clm_781C2FB5DFBA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465914036968/0001104659-14-036968-index.htm.","url":"https://asof.is/claim/clm_781C2FB5DFBA","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,351,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_781C2FB5DFBA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2014, filed 2014-05-09"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 28,657,000,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_97E99E151E53, https://asof.is/claim/clm_97E99E151E53, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465914036968/0001104659-14-036968-index.htm.","url":"https://asof.is/claim/clm_97E99E151E53","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"28,657,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_97E99E151E53","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2014, filed 2014-05-09"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,590,066,459 shares\", as of 2014-03-31 (until 2014-06-30). Claim clm_A4E4164393FB, https://asof.is/claim/clm_A4E4164393FB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465914036968/0001104659-14-036968-index.htm.","url":"https://asof.is/claim/clm_A4E4164393FB","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,590,066,459 shares","status":"superseded","assertable":true,"id":"clm_A4E4164393FB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2014, filed 2014-05-09"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 29,045,000,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_42B02BB64DBB, https://asof.is/claim/clm_42B02BB64DBB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465914058340/0001104659-14-058340-index.htm.","url":"https://asof.is/claim/clm_42B02BB64DBB","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"29,045,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_42B02BB64DBB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2014, filed 2014-08-07"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,591,699,124 shares\", as of 2014-06-30 (until 2014-09-30). Claim clm_8AD2A24EAFA5, https://asof.is/claim/clm_8AD2A24EAFA5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465914058340/0001104659-14-058340-index.htm.","url":"https://asof.is/claim/clm_8AD2A24EAFA5","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,591,699,124 shares","status":"superseded","assertable":true,"id":"clm_8AD2A24EAFA5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2014, filed 2014-08-07"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 9,086,000,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_A2860DB7C8A4, https://asof.is/claim/clm_A2860DB7C8A4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465914058340/0001104659-14-058340-index.htm.","url":"https://asof.is/claim/clm_A2860DB7C8A4","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"9,086,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A2860DB7C8A4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2014, filed 2014-08-07"}},{"date":"2014-06-30","until":"2014-09-30","published":"2015-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 4,926,000,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_DA4F15CF335B, https://asof.is/claim/clm_DA4F15CF335B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465915057641/0001104659-15-057641-index.htm.","url":"https://asof.is/claim/clm_DA4F15CF335B","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"4,926,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DA4F15CF335B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2015, filed 2015-08-07"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 5,218,000,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_E3CE62EE8803, https://asof.is/claim/clm_E3CE62EE8803, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465914058340/0001104659-14-058340-index.htm.","url":"https://asof.is/claim/clm_E3CE62EE8803","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"5,218,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E3CE62EE8803","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2014, filed 2014-08-07"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 1,515,000,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_F8769037DF45, https://asof.is/claim/clm_F8769037DF45, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465914058340/0001104659-14-058340-index.htm.","url":"https://asof.is/claim/clm_F8769037DF45","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,515,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F8769037DF45","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2014, filed 2014-08-07"}},{"date":"2014-09-30","until":"2014-12-31","published":"2014-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 28,454,000,000 United States dollar\", as of 2014-09-30 (until 2014-12-31). Claim clm_1BEC5D77F87E, https://asof.is/claim/clm_1BEC5D77F87E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465914078391/0001104659-14-078391-index.htm.","url":"https://asof.is/claim/clm_1BEC5D77F87E","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"28,454,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1BEC5D77F87E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2014, filed 2014-11-07"}},{"date":"2014-09-30","until":"2014-12-31","published":"2014-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 4,645,000,000 United States dollar\", as of 2014-09-30 (until 2014-12-31). Claim clm_70ABDD4E760D, https://asof.is/claim/clm_70ABDD4E760D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465914078391/0001104659-14-078391-index.htm.","url":"https://asof.is/claim/clm_70ABDD4E760D","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"4,645,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_70ABDD4E760D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2014, filed 2014-11-07"}},{"date":"2014-09-30","until":"2015-03-31","published":"2014-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 960,000,000 United States dollar\", as of 2014-09-30 (until 2015-03-31). Claim clm_9A141AD4FB42, https://asof.is/claim/clm_9A141AD4FB42, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465914078391/0001104659-14-078391-index.htm.","url":"https://asof.is/claim/clm_9A141AD4FB42","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"960,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9A141AD4FB42","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2014, filed 2014-11-07"}},{"date":"2014-09-30","until":"2014-12-31","published":"2014-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 7,719,000,000 United States dollar\", as of 2014-09-30 (until 2014-12-31). Claim clm_A6644DA6B8CD, https://asof.is/claim/clm_A6644DA6B8CD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465914078391/0001104659-14-078391-index.htm.","url":"https://asof.is/claim/clm_A6644DA6B8CD","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"7,719,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A6644DA6B8CD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2014, filed 2014-11-07"}},{"date":"2014-09-30","until":"2015-03-31","published":"2015-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 5,019,000,000 United States dollar\", as of 2014-09-30 (until 2015-03-31). Claim clm_A7029DF5DA96, https://asof.is/claim/clm_A7029DF5DA96, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465915076607/0001104659-15-076607-index.htm.","url":"https://asof.is/claim/clm_A7029DF5DA96","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"5,019,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A7029DF5DA96","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2015, filed 2015-11-06"}},{"date":"2014-09-30","until":"2015-01-31","published":"2014-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,593,265,381 shares\", as of 2014-09-30 (until 2015-01-31). Claim clm_F79C518E8FAA, https://asof.is/claim/clm_F79C518E8FAA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465914078391/0001104659-14-078391-index.htm.","url":"https://asof.is/claim/clm_F79C518E8FAA","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,593,265,381 shares","status":"superseded","assertable":true,"id":"clm_F79C518E8FAA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2014, filed 2014-11-07"}},{"date":"2014-12-31","until":"2015-03-31","published":"2015-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 1,742,000,000 United States dollar\", as of 2014-12-31 (until 2015-03-31). Claim clm_1D6156E5BADB, https://asof.is/claim/clm_1D6156E5BADB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746915000995/0001047469-15-000995-index.htm.","url":"https://asof.is/claim/clm_1D6156E5BADB","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"1,742,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1D6156E5BADB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2014, filed 2015-02-20"}},{"date":"2014-12-31","until":"2015-12-31","published":"2015-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie revenue: 19,960,000,000 United States dollar\", as of 2014-12-31 (until 2015-12-31). Claim clm_3A0D33F3133A, https://asof.is/claim/clm_3A0D33F3133A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746915000995/0001047469-15-000995-index.htm.","url":"https://asof.is/claim/clm_3A0D33F3133A","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"19,960,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3A0D33F3133A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-K FY2014, filed 2015-02-20"}},{"date":"2014-12-31","until":"2015-12-31","published":"2015-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie operating income: 3,411,000,000 United States dollar\", as of 2014-12-31 (until 2015-12-31). Claim clm_5420B85B9EF4, https://asof.is/claim/clm_5420B85B9EF4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746915000995/0001047469-15-000995-index.htm.","url":"https://asof.is/claim/clm_5420B85B9EF4","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"3,411,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5420B85B9EF4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2014, filed 2015-02-20"}},{"date":"2014-12-31","until":"2015-12-31","published":"2017-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie net income: 1,774,000,000 United States dollar\", as of 2014-12-31 (until 2015-12-31). Claim clm_C1C38D8E4FB1, https://asof.is/claim/clm_C1C38D8E4FB1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000004/0001551152-17-000004-index.htm.","url":"https://asof.is/claim/clm_C1C38D8E4FB1","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"1,774,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C1C38D8E4FB1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2016, filed 2017-02-17"}},{"date":"2014-12-31","until":"2015-03-31","published":"2015-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 8,348,000,000 United States dollar\", as of 2014-12-31 (until 2015-03-31). Claim clm_DCCC204D0954, https://asof.is/claim/clm_DCCC204D0954, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746915000995/0001047469-15-000995-index.htm.","url":"https://asof.is/claim/clm_DCCC204D0954","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"8,348,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DCCC204D0954","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2014, filed 2015-02-20"}},{"date":"2014-12-31","until":"2015-03-31","published":"2015-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 27,547,000,000 United States dollar\", as of 2014-12-31 (until 2015-03-31). Claim clm_EB461D77BDD4, https://asof.is/claim/clm_EB461D77BDD4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746915000995/0001047469-15-000995-index.htm.","url":"https://asof.is/claim/clm_EB461D77BDD4","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"27,547,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EB461D77BDD4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2014, filed 2015-02-20"}},{"date":"2015-01-31","until":"2015-03-31","published":"2015-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,593,886,909 shares\", as of 2015-01-31 (until 2015-03-31). Claim clm_7FD76082DBAA, https://asof.is/claim/clm_7FD76082DBAA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746915000995/0001047469-15-000995-index.htm.","url":"https://asof.is/claim/clm_7FD76082DBAA","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,593,886,909 shares","status":"superseded","assertable":true,"id":"clm_7FD76082DBAA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2014, filed 2015-02-20"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 1,687,000,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_12DF3E454E71, https://asof.is/claim/clm_12DF3E454E71, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465915036257/0001104659-15-036257-index.htm.","url":"https://asof.is/claim/clm_12DF3E454E71","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,687,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_12DF3E454E71","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2015, filed 2015-05-08"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,593,076,097 shares\", as of 2015-03-31 (until 2015-06-30). Claim clm_1A9033C7E5CD, https://asof.is/claim/clm_1A9033C7E5CD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465915036257/0001104659-15-036257-index.htm.","url":"https://asof.is/claim/clm_1A9033C7E5CD","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,593,076,097 shares","status":"superseded","assertable":true,"id":"clm_1A9033C7E5CD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2015, filed 2015-05-08"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 7,906,000,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_B187D122E493, https://asof.is/claim/clm_B187D122E493, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465915036257/0001104659-15-036257-index.htm.","url":"https://asof.is/claim/clm_B187D122E493","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"7,906,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B187D122E493","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2015, filed 2015-05-08"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 26,699,000,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_D450CCC758EE, https://asof.is/claim/clm_D450CCC758EE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465915036257/0001104659-15-036257-index.htm.","url":"https://asof.is/claim/clm_D450CCC758EE","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"26,699,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D450CCC758EE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2015, filed 2015-05-08"}},{"date":"2015-03-31","until":"2015-06-30","published":"2016-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 5,040,000,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_EEF0B5482085, https://asof.is/claim/clm_EEF0B5482085, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465916118639/0001104659-16-118639-index.htm.","url":"https://asof.is/claim/clm_EEF0B5482085","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"5,040,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EEF0B5482085","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2016, filed 2016-05-06"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 1,377,000,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_F432E94DBFE8, https://asof.is/claim/clm_F432E94DBFE8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465915036257/0001104659-15-036257-index.htm.","url":"https://asof.is/claim/clm_F432E94DBFE8","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"1,377,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F432E94DBFE8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2015, filed 2015-05-08"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 7,400,000,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_11F80DB2CE1F, https://asof.is/claim/clm_11F80DB2CE1F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465915057641/0001104659-15-057641-index.htm.","url":"https://asof.is/claim/clm_11F80DB2CE1F","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"7,400,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_11F80DB2CE1F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2015, filed 2015-08-07"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 1,852,000,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_20801B67DB71, https://asof.is/claim/clm_20801B67DB71, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465915057641/0001104659-15-057641-index.htm.","url":"https://asof.is/claim/clm_20801B67DB71","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,852,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_20801B67DB71","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2015, filed 2015-08-07"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 5,504,000,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_213580F78FFD, https://asof.is/claim/clm_213580F78FFD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465915057641/0001104659-15-057641-index.htm.","url":"https://asof.is/claim/clm_213580F78FFD","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"5,504,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_213580F78FFD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2015, filed 2015-08-07"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,655,276,338 shares\", as of 2015-06-30 (until 2015-09-30). Claim clm_23EC71200821, https://asof.is/claim/clm_23EC71200821, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465915057641/0001104659-15-057641-index.htm.","url":"https://asof.is/claim/clm_23EC71200821","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,655,276,338 shares","status":"superseded","assertable":true,"id":"clm_23EC71200821","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2015, filed 2015-08-07"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 5,475,000,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_C287D4F05535, https://asof.is/claim/clm_C287D4F05535, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465915057641/0001104659-15-057641-index.htm.","url":"https://asof.is/claim/clm_C287D4F05535","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"5,475,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C287D4F05535","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2015, filed 2015-08-07"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 53,855,000,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_D42809778327, https://asof.is/claim/clm_D42809778327, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465915057641/0001104659-15-057641-index.htm.","url":"https://asof.is/claim/clm_D42809778327","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"53,855,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D42809778327","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2015, filed 2015-08-07"}},{"date":"2015-09-30","until":"2016-01-31","published":"2015-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,634,746,917 shares\", as of 2015-09-30 (until 2016-01-31). Claim clm_3ACFDECAD445, https://asof.is/claim/clm_3ACFDECAD445, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465915076607/0001104659-15-076607-index.htm.","url":"https://asof.is/claim/clm_3ACFDECAD445","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,634,746,917 shares","status":"superseded","assertable":true,"id":"clm_3ACFDECAD445","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2015, filed 2015-11-06"}},{"date":"2015-09-30","until":"2015-12-31","published":"2015-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 54,832,000,000 United States dollar\", as of 2015-09-30 (until 2015-12-31). Claim clm_5BFD83100796, https://asof.is/claim/clm_5BFD83100796, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465915076607/0001104659-15-076607-index.htm.","url":"https://asof.is/claim/clm_5BFD83100796","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"54,832,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5BFD83100796","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2015, filed 2015-11-06"}},{"date":"2015-09-30","until":"2015-12-31","published":"2015-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 4,863,000,000 United States dollar\", as of 2015-09-30 (until 2015-12-31). Claim clm_6F0CD2AA2AA9, https://asof.is/claim/clm_6F0CD2AA2AA9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465915076607/0001104659-15-076607-index.htm.","url":"https://asof.is/claim/clm_6F0CD2AA2AA9","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"4,863,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6F0CD2AA2AA9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2015, filed 2015-11-06"}},{"date":"2015-09-30","until":"2016-03-31","published":"2016-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 1,239,000,000 United States dollar\", as of 2015-09-30 (until 2016-03-31). Claim clm_91D5FCA6D338, https://asof.is/claim/clm_91D5FCA6D338, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115216000005/0001551152-16-000005-index.htm.","url":"https://asof.is/claim/clm_91D5FCA6D338","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,239,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_91D5FCA6D338","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2016, filed 2016-11-07"}},{"date":"2015-09-30","until":"2016-03-31","published":"2015-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 5,944,000,000 United States dollar\", as of 2015-09-30 (until 2016-03-31). Claim clm_9DB567EABED1, https://asof.is/claim/clm_9DB567EABED1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465915076607/0001104659-15-076607-index.htm.","url":"https://asof.is/claim/clm_9DB567EABED1","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"5,944,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9DB567EABED1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2015, filed 2015-11-06"}},{"date":"2015-09-30","until":"2016-03-31","published":"2015-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 1,885,000,000 United States dollar\", as of 2015-09-30 (until 2016-03-31). Claim clm_A3F1416FDC9E, https://asof.is/claim/clm_A3F1416FDC9E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465915076607/0001104659-15-076607-index.htm.","url":"https://asof.is/claim/clm_A3F1416FDC9E","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,885,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A3F1416FDC9E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2015, filed 2015-11-06"}},{"date":"2015-09-30","until":"2015-12-31","published":"2015-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 9,223,000,000 United States dollar\", as of 2015-09-30 (until 2015-12-31). Claim clm_CE1D0788C2C4, https://asof.is/claim/clm_CE1D0788C2C4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465915076607/0001104659-15-076607-index.htm.","url":"https://asof.is/claim/clm_CE1D0788C2C4","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"9,223,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CE1D0788C2C4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2015, filed 2015-11-06"}},{"date":"2015-12-31","until":"2016-12-31","published":"2016-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie operating income: 7,537,000,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_3F2A5C2764AA, https://asof.is/claim/clm_3F2A5C2764AA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746916010239/0001047469-16-010239-index.htm.","url":"https://asof.is/claim/clm_3F2A5C2764AA","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"7,537,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3F2A5C2764AA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2015, filed 2016-02-19"}},{"date":"2015-12-31","until":"2016-03-31","published":"2016-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 3,945,000,000 United States dollar\", as of 2015-12-31 (until 2016-03-31). Claim clm_6F4282E76FED, https://asof.is/claim/clm_6F4282E76FED, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746916010239/0001047469-16-010239-index.htm.","url":"https://asof.is/claim/clm_6F4282E76FED","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"3,945,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6F4282E76FED","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2015, filed 2016-02-19"}},{"date":"2015-12-31","until":"2016-12-31","published":"2016-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie revenue: 22,859,000,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_778004ECC385, https://asof.is/claim/clm_778004ECC385, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746916010239/0001047469-16-010239-index.htm.","url":"https://asof.is/claim/clm_778004ECC385","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"22,859,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_778004ECC385","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-K FY2015, filed 2016-02-19"}},{"date":"2015-12-31","until":"2016-03-31","published":"2016-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 8,399,000,000 United States dollar\", as of 2015-12-31 (until 2016-03-31). Claim clm_78885045199F, https://asof.is/claim/clm_78885045199F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746916010239/0001047469-16-010239-index.htm.","url":"https://asof.is/claim/clm_78885045199F","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"8,399,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_78885045199F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2015, filed 2016-02-19"}},{"date":"2015-12-31","until":"2016-03-31","published":"2016-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 53,050,000,000 United States dollar\", as of 2015-12-31 (until 2016-03-31). Claim clm_D36BDE4DBD80, https://asof.is/claim/clm_D36BDE4DBD80, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746916010239/0001047469-16-010239-index.htm.","url":"https://asof.is/claim/clm_D36BDE4DBD80","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"53,050,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D36BDE4DBD80","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2015, filed 2016-02-19"}},{"date":"2015-12-31","until":"2016-12-31","published":"2017-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie net income: 5,144,000,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_E3B87E01B082, https://asof.is/claim/clm_E3B87E01B082, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000004/0001551152-17-000004-index.htm.","url":"https://asof.is/claim/clm_E3B87E01B082","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"5,144,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E3B87E01B082","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2016, filed 2017-02-17"}},{"date":"2016-01-31","until":"2016-03-31","published":"2016-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,611,238,226 shares\", as of 2016-01-31 (until 2016-03-31). Claim clm_66A3F5820C42, https://asof.is/claim/clm_66A3F5820C42, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746916010239/0001047469-16-010239-index.htm.","url":"https://asof.is/claim/clm_66A3F5820C42","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,611,238,226 shares","status":"superseded","assertable":true,"id":"clm_66A3F5820C42","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2015, filed 2016-02-19"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 4,643,000,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_1C685783785E, https://asof.is/claim/clm_1C685783785E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465916118639/0001104659-16-118639-index.htm.","url":"https://asof.is/claim/clm_1C685783785E","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"4,643,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1C685783785E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2016, filed 2016-05-06"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,617,358,607 shares\", as of 2016-03-31 (until 2016-06-30). Claim clm_3387E7EBA81F, https://asof.is/claim/clm_3387E7EBA81F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465916118639/0001104659-16-118639-index.htm.","url":"https://asof.is/claim/clm_3387E7EBA81F","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,617,358,607 shares","status":"superseded","assertable":true,"id":"clm_3387E7EBA81F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2016, filed 2016-05-06"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 5,958,000,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_50CDB8FC3EC3, https://asof.is/claim/clm_50CDB8FC3EC3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465916118639/0001104659-16-118639-index.htm.","url":"https://asof.is/claim/clm_50CDB8FC3EC3","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"5,958,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_50CDB8FC3EC3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2016, filed 2016-05-06"}},{"date":"2016-03-31","until":"2016-06-30","published":"2017-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 1,354,000,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_55698570AC31, https://asof.is/claim/clm_55698570AC31, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000016/0001551152-17-000016-index.htm.","url":"https://asof.is/claim/clm_55698570AC31","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,354,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_55698570AC31","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2017, filed 2017-05-05"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 2,278,000,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_DCD9157C9133, https://asof.is/claim/clm_DCD9157C9133, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465916118639/0001104659-16-118639-index.htm.","url":"https://asof.is/claim/clm_DCD9157C9133","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"2,278,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DCD9157C9133","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2016, filed 2016-05-06"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 53,720,000,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_DCE037E09A9F, https://asof.is/claim/clm_DCE037E09A9F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465916118639/0001104659-16-118639-index.htm.","url":"https://asof.is/claim/clm_DCE037E09A9F","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"53,720,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DCE037E09A9F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2016, filed 2016-05-06"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 7,556,000,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_FC08DA3650E9, https://asof.is/claim/clm_FC08DA3650E9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465916118639/0001104659-16-118639-index.htm.","url":"https://asof.is/claim/clm_FC08DA3650E9","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"7,556,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FC08DA3650E9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2016, filed 2016-05-06"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 67,211,000,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_10BA5050BC7D, https://asof.is/claim/clm_10BA5050BC7D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465916137453/0001104659-16-137453-index.htm.","url":"https://asof.is/claim/clm_10BA5050BC7D","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"67,211,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_10BA5050BC7D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2016, filed 2016-08-05"}},{"date":"2016-06-30","until":"2016-10-24","published":"2016-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,628,542,359 shares\", as of 2016-06-30 (until 2016-10-24). Claim clm_28EEE079F857, https://asof.is/claim/clm_28EEE079F857, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465916137453/0001104659-16-137453-index.htm.","url":"https://asof.is/claim/clm_28EEE079F857","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,628,542,359 shares","status":"superseded","assertable":true,"id":"clm_28EEE079F857","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2016, filed 2016-08-05"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 5,640,000,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_2ED4D5DFDB0F, https://asof.is/claim/clm_2ED4D5DFDB0F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465916137453/0001104659-16-137453-index.htm.","url":"https://asof.is/claim/clm_2ED4D5DFDB0F","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"5,640,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2ED4D5DFDB0F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2016, filed 2016-08-05"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 6,327,000,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_307C886B12A3, https://asof.is/claim/clm_307C886B12A3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465916137453/0001104659-16-137453-index.htm.","url":"https://asof.is/claim/clm_307C886B12A3","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"6,327,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_307C886B12A3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2016, filed 2016-08-05"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 2,387,000,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_B8181F382DF3, https://asof.is/claim/clm_B8181F382DF3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465916137453/0001104659-16-137453-index.htm.","url":"https://asof.is/claim/clm_B8181F382DF3","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"2,387,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B8181F382DF3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2016, filed 2016-08-05"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 6,452,000,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_E445263E135D, https://asof.is/claim/clm_E445263E135D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465916137453/0001104659-16-137453-index.htm.","url":"https://asof.is/claim/clm_E445263E135D","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"6,452,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E445263E135D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2016, filed 2016-08-05"}},{"date":"2016-06-30","until":"2016-09-30","published":"2017-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 1,610,000,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_F99B3D3C908F, https://asof.is/claim/clm_F99B3D3C908F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000025/0001551152-17-000025-index.htm.","url":"https://asof.is/claim/clm_F99B3D3C908F","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,610,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F99B3D3C908F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2017, filed 2017-08-07"}},{"date":"2016-09-30","until":"2017-03-31","published":"2016-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 6,432,000,000 United States dollar\", as of 2016-09-30 (until 2017-03-31). Claim clm_2A4B013AE0D7, https://asof.is/claim/clm_2A4B013AE0D7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115216000005/0001551152-16-000005-index.htm.","url":"https://asof.is/claim/clm_2A4B013AE0D7","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"6,432,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2A4B013AE0D7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2016, filed 2016-11-07"}},{"date":"2016-09-30","until":"2017-03-31","published":"2016-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 1,598,000,000 United States dollar\", as of 2016-09-30 (until 2017-03-31). Claim clm_573466154ABF, https://asof.is/claim/clm_573466154ABF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115216000005/0001551152-16-000005-index.htm.","url":"https://asof.is/claim/clm_573466154ABF","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,598,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_573466154ABF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2016, filed 2016-11-07"}},{"date":"2016-09-30","until":"2016-12-31","published":"2016-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 6,218,000,000 United States dollar\", as of 2016-09-30 (until 2016-12-31). Claim clm_79527B6A026A, https://asof.is/claim/clm_79527B6A026A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115216000005/0001551152-16-000005-index.htm.","url":"https://asof.is/claim/clm_79527B6A026A","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"6,218,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_79527B6A026A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2016, filed 2016-11-07"}},{"date":"2016-09-30","until":"2017-03-31","published":"2016-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 2,361,000,000 United States dollar\", as of 2016-09-30 (until 2017-03-31). Claim clm_B4012167F64D, https://asof.is/claim/clm_B4012167F64D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115216000005/0001551152-16-000005-index.htm.","url":"https://asof.is/claim/clm_B4012167F64D","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"2,361,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B4012167F64D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2016, filed 2016-11-07"}},{"date":"2016-09-30","until":"2016-12-31","published":"2016-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 66,626,000,000 United States dollar\", as of 2016-09-30 (until 2016-12-31). Claim clm_B9C574866001, https://asof.is/claim/clm_B9C574866001, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115216000005/0001551152-16-000005-index.htm.","url":"https://asof.is/claim/clm_B9C574866001","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"66,626,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B9C574866001","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2016, filed 2016-11-07"}},{"date":"2016-09-30","until":"2016-12-31","published":"2016-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 6,469,000,000 United States dollar\", as of 2016-09-30 (until 2016-12-31). Claim clm_C5F4EFA54CAC, https://asof.is/claim/clm_C5F4EFA54CAC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115216000005/0001551152-16-000005-index.htm.","url":"https://asof.is/claim/clm_C5F4EFA54CAC","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"6,469,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C5F4EFA54CAC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2016, filed 2016-11-07"}},{"date":"2016-10-24","until":"2017-01-31","published":"2016-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,625,099,012 shares\", as of 2016-10-24 (until 2017-01-31). Claim clm_026545419A27, https://asof.is/claim/clm_026545419A27, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115216000005/0001551152-16-000005-index.htm.","url":"https://asof.is/claim/clm_026545419A27","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,625,099,012 shares","status":"superseded","assertable":true,"id":"clm_026545419A27","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2016, filed 2016-11-07"}},{"date":"2016-12-31","until":"2017-03-31","published":"2017-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 4,636,000,000 United States dollar\", as of 2016-12-31 (until 2017-03-31). Claim clm_05B8B5516E3C, https://asof.is/claim/clm_05B8B5516E3C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000004/0001551152-17-000004-index.htm.","url":"https://asof.is/claim/clm_05B8B5516E3C","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"4,636,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_05B8B5516E3C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2016, filed 2017-02-17"}},{"date":"2016-12-31","until":"2017-03-31","published":"2017-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 66,099,000,000 United States dollar\", as of 2016-12-31 (until 2017-03-31). Claim clm_94513531556F, https://asof.is/claim/clm_94513531556F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000004/0001551152-17-000004-index.htm.","url":"https://asof.is/claim/clm_94513531556F","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"66,099,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_94513531556F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2016, filed 2017-02-17"}},{"date":"2016-12-31","until":"2017-12-31","published":"2019-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie revenue: 25,638,000,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_B8A18C367510, https://asof.is/claim/clm_B8A18C367510, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000008/0001551152-19-000008-index.htm.","url":"https://asof.is/claim/clm_B8A18C367510","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"25,638,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B8A18C367510","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2018, filed 2019-02-27"}},{"date":"2016-12-31","until":"2017-03-31","published":"2017-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 5,100,000,000 United States dollar\", as of 2016-12-31 (until 2017-03-31). Claim clm_CFE5A45B27A0, https://asof.is/claim/clm_CFE5A45B27A0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000004/0001551152-17-000004-index.htm.","url":"https://asof.is/claim/clm_CFE5A45B27A0","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"5,100,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CFE5A45B27A0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2016, filed 2017-02-17"}},{"date":"2016-12-31","until":"2017-12-31","published":"2017-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie operating income: 9,384,000,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_D0B092E67442, https://asof.is/claim/clm_D0B092E67442, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000004/0001551152-17-000004-index.htm.","url":"https://asof.is/claim/clm_D0B092E67442","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"9,384,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D0B092E67442","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2016, filed 2017-02-17"}},{"date":"2016-12-31","until":"2017-12-31","published":"2017-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie net income: 5,953,000,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_F05A32E90FA3, https://asof.is/claim/clm_F05A32E90FA3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000004/0001551152-17-000004-index.htm.","url":"https://asof.is/claim/clm_F05A32E90FA3","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"5,953,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F05A32E90FA3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2016, filed 2017-02-17"}},{"date":"2017-01-31","until":"2017-04-24","published":"2017-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,593,920,285 shares\", as of 2017-01-31 (until 2017-04-24). Claim clm_DA54BBD2450C, https://asof.is/claim/clm_DA54BBD2450C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000004/0001551152-17-000004-index.htm.","url":"https://asof.is/claim/clm_DA54BBD2450C","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,593,920,285 shares","status":"superseded","assertable":true,"id":"clm_DA54BBD2450C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2016, filed 2017-02-17"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 1,711,000,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_17D012C87892, https://asof.is/claim/clm_17D012C87892, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000016/0001551152-17-000016-index.htm.","url":"https://asof.is/claim/clm_17D012C87892","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,711,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_17D012C87892","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2017, filed 2017-05-05"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 4,998,000,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_1D4001B02D65, https://asof.is/claim/clm_1D4001B02D65, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000016/0001551152-17-000016-index.htm.","url":"https://asof.is/claim/clm_1D4001B02D65","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"4,998,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1D4001B02D65","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2017, filed 2017-05-05"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 2,419,000,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_7516913F42F9, https://asof.is/claim/clm_7516913F42F9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000016/0001551152-17-000016-index.htm.","url":"https://asof.is/claim/clm_7516913F42F9","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"2,419,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7516913F42F9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2017, filed 2017-05-05"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 6,538,000,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_91E1E8F4CFBF, https://asof.is/claim/clm_91E1E8F4CFBF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000016/0001551152-17-000016-index.htm.","url":"https://asof.is/claim/clm_91E1E8F4CFBF","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"6,538,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_91E1E8F4CFBF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2017, filed 2017-05-05"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 4,740,000,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_94C338ACD4BE, https://asof.is/claim/clm_94C338ACD4BE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000016/0001551152-17-000016-index.htm.","url":"https://asof.is/claim/clm_94C338ACD4BE","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"4,740,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_94C338ACD4BE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2017, filed 2017-05-05"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 65,664,000,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_A31DA02730CF, https://asof.is/claim/clm_A31DA02730CF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000016/0001551152-17-000016-index.htm.","url":"https://asof.is/claim/clm_A31DA02730CF","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"65,664,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A31DA02730CF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2017, filed 2017-05-05"}},{"date":"2017-04-24","until":"2017-07-24","published":"2017-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,591,540,513 shares\", as of 2017-04-24 (until 2017-07-24). Claim clm_A12CA3DA4AB9, https://asof.is/claim/clm_A12CA3DA4AB9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000016/0001551152-17-000016-index.htm.","url":"https://asof.is/claim/clm_A12CA3DA4AB9","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,591,540,513 shares","status":"superseded","assertable":true,"id":"clm_A12CA3DA4AB9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2017, filed 2017-05-05"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 6,009,000,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_3CB07593AF7C, https://asof.is/claim/clm_3CB07593AF7C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000025/0001551152-17-000025-index.htm.","url":"https://asof.is/claim/clm_3CB07593AF7C","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"6,009,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3CB07593AF7C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2017, filed 2017-08-07"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 2,674,000,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_504B0BC83B6A, https://asof.is/claim/clm_504B0BC83B6A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000025/0001551152-17-000025-index.htm.","url":"https://asof.is/claim/clm_504B0BC83B6A","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"2,674,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_504B0BC83B6A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2017, filed 2017-08-07"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 6,944,000,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_57888AB73869, https://asof.is/claim/clm_57888AB73869, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000025/0001551152-17-000025-index.htm.","url":"https://asof.is/claim/clm_57888AB73869","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"6,944,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_57888AB73869","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2017, filed 2017-08-07"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 1,915,000,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_5E4C2023B96B, https://asof.is/claim/clm_5E4C2023B96B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000025/0001551152-17-000025-index.htm.","url":"https://asof.is/claim/clm_5E4C2023B96B","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,915,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5E4C2023B96B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2017, filed 2017-08-07"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 66,994,000,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_B5248F34B0B8, https://asof.is/claim/clm_B5248F34B0B8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000025/0001551152-17-000025-index.htm.","url":"https://asof.is/claim/clm_B5248F34B0B8","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"66,994,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B5248F34B0B8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2017, filed 2017-08-07"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 6,088,000,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_F0AF41EB2CBC, https://asof.is/claim/clm_F0AF41EB2CBC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000025/0001551152-17-000025-index.htm.","url":"https://asof.is/claim/clm_F0AF41EB2CBC","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"6,088,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F0AF41EB2CBC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2017, filed 2017-08-07"}},{"date":"2017-07-24","until":"2017-10-24","published":"2017-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,594,094,698 shares\", as of 2017-07-24 (until 2017-10-24). Claim clm_95C323AFFAFB, https://asof.is/claim/clm_95C323AFFAFB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000025/0001551152-17-000025-index.htm.","url":"https://asof.is/claim/clm_95C323AFFAFB","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,594,094,698 shares","status":"superseded","assertable":true,"id":"clm_95C323AFFAFB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2017, filed 2017-08-07"}},{"date":"2017-09-30","until":"2018-03-31","published":"2017-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 1,631,000,000 United States dollar\", as of 2017-09-30 (until 2018-03-31). Claim clm_013E1D0CE6A0, https://asof.is/claim/clm_013E1D0CE6A0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000035/0001551152-17-000035-index.htm.","url":"https://asof.is/claim/clm_013E1D0CE6A0","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,631,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_013E1D0CE6A0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2017, filed 2017-11-07"}},{"date":"2017-09-30","until":"2017-12-31","published":"2017-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 6,687,000,000 United States dollar\", as of 2017-09-30 (until 2017-12-31). Claim clm_4023A402BB1E, https://asof.is/claim/clm_4023A402BB1E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000035/0001551152-17-000035-index.htm.","url":"https://asof.is/claim/clm_4023A402BB1E","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"6,687,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4023A402BB1E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2017, filed 2017-11-07"}},{"date":"2017-09-30","until":"2018-03-31","published":"2017-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 2,705,000,000 United States dollar\", as of 2017-09-30 (until 2018-03-31). Claim clm_5B10BBC2BC51, https://asof.is/claim/clm_5B10BBC2BC51, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000035/0001551152-17-000035-index.htm.","url":"https://asof.is/claim/clm_5B10BBC2BC51","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"2,705,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5B10BBC2BC51","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2017, filed 2017-11-07"}},{"date":"2017-09-30","until":"2018-03-31","published":"2017-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 6,995,000,000 United States dollar\", as of 2017-09-30 (until 2018-03-31). Claim clm_6578B80CE1C3, https://asof.is/claim/clm_6578B80CE1C3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000035/0001551152-17-000035-index.htm.","url":"https://asof.is/claim/clm_6578B80CE1C3","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"6,995,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6578B80CE1C3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2017, filed 2017-11-07"}},{"date":"2017-09-30","until":"2017-12-31","published":"2017-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 68,840,000,000 United States dollar\", as of 2017-09-30 (until 2017-12-31). Claim clm_E218878A198F, https://asof.is/claim/clm_E218878A198F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000035/0001551152-17-000035-index.htm.","url":"https://asof.is/claim/clm_E218878A198F","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"68,840,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E218878A198F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2017, filed 2017-11-07"}},{"date":"2017-09-30","until":"2017-12-31","published":"2017-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 8,446,000,000 United States dollar\", as of 2017-09-30 (until 2017-12-31). Claim clm_ED592A963798, https://asof.is/claim/clm_ED592A963798, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000035/0001551152-17-000035-index.htm.","url":"https://asof.is/claim/clm_ED592A963798","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"8,446,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_ED592A963798","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2017, filed 2017-11-07"}},{"date":"2017-10-24","until":"2018-02-02","published":"2017-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,596,429,740 shares\", as of 2017-10-24 (until 2018-02-02). Claim clm_91E5B93BAAD8, https://asof.is/claim/clm_91E5B93BAAD8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000035/0001551152-17-000035-index.htm.","url":"https://asof.is/claim/clm_91E5B93BAAD8","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,596,429,740 shares","status":"superseded","assertable":true,"id":"clm_91E5B93BAAD8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2017, filed 2017-11-07"}},{"date":"2017-12-31","until":"2018-03-31","published":"2018-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 70,786,000,000 United States dollar\", as of 2017-12-31 (until 2018-03-31). Claim clm_212B72E3191E, https://asof.is/claim/clm_212B72E3191E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000014/0001551152-18-000014-index.htm.","url":"https://asof.is/claim/clm_212B72E3191E","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"70,786,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_212B72E3191E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2017, filed 2018-02-16"}},{"date":"2017-12-31","until":"2018-12-31","published":"2018-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie operating income: 9,592,000,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_386A79CBE5AB, https://asof.is/claim/clm_386A79CBE5AB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000014/0001551152-18-000014-index.htm.","url":"https://asof.is/claim/clm_386A79CBE5AB","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"9,592,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_386A79CBE5AB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2017, filed 2018-02-16"}},{"date":"2017-12-31","until":"2018-03-31","published":"2018-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 5,097,000,000 United States dollar\", as of 2017-12-31 (until 2018-03-31). Claim clm_512AA9C989B0, https://asof.is/claim/clm_512AA9C989B0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000014/0001551152-18-000014-index.htm.","url":"https://asof.is/claim/clm_512AA9C989B0","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"5,097,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_512AA9C989B0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2017, filed 2018-02-16"}},{"date":"2017-12-31","until":"2018-12-31","published":"2019-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie revenue: 28,216,000,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_9C790281A637, https://asof.is/claim/clm_9C790281A637, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000008/0001551152-19-000008-index.htm.","url":"https://asof.is/claim/clm_9C790281A637","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"28,216,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9C790281A637","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2018, filed 2019-02-27"}},{"date":"2017-12-31","until":"2018-12-31","published":"2018-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie net income: 5,309,000,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_C95C497479DE, https://asof.is/claim/clm_C95C497479DE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000014/0001551152-18-000014-index.htm.","url":"https://asof.is/claim/clm_C95C497479DE","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"5,309,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C95C497479DE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2017, filed 2018-02-16"}},{"date":"2017-12-31","until":"2018-03-31","published":"2018-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 9,303,000,000 United States dollar\", as of 2017-12-31 (until 2018-03-31). Claim clm_D8002DD7DB3E, https://asof.is/claim/clm_D8002DD7DB3E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000014/0001551152-18-000014-index.htm.","url":"https://asof.is/claim/clm_D8002DD7DB3E","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"9,303,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D8002DD7DB3E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2017, filed 2018-02-16"}},{"date":"2018-02-02","until":"2018-04-27","published":"2018-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,587,972,655 shares\", as of 2018-02-02 (until 2018-04-27). Claim clm_DA1BB2B2421A, https://asof.is/claim/clm_DA1BB2B2421A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000014/0001551152-18-000014-index.htm.","url":"https://asof.is/claim/clm_DA1BB2B2421A","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,587,972,655 shares","status":"superseded","assertable":true,"id":"clm_DA1BB2B2421A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2017, filed 2018-02-16"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 2,903,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_2F093617D53B, https://asof.is/claim/clm_2F093617D53B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000025/0001551152-18-000025-index.htm.","url":"https://asof.is/claim/clm_2F093617D53B","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"2,903,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2F093617D53B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2018, filed 2018-05-04"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 9,007,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_5A3AC951CCFF, https://asof.is/claim/clm_5A3AC951CCFF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000025/0001551152-18-000025-index.htm.","url":"https://asof.is/claim/clm_5A3AC951CCFF","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"9,007,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5A3AC951CCFF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2018, filed 2018-05-04"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 7,934,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_638ECD9CFFA0, https://asof.is/claim/clm_638ECD9CFFA0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000025/0001551152-18-000025-index.htm.","url":"https://asof.is/claim/clm_638ECD9CFFA0","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"7,934,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_638ECD9CFFA0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2018, filed 2018-05-04"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 2,783,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_A64BC7BE871E, https://asof.is/claim/clm_A64BC7BE871E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000025/0001551152-18-000025-index.htm.","url":"https://asof.is/claim/clm_A64BC7BE871E","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"2,783,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A64BC7BE871E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2018, filed 2018-05-04"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 3,553,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_B65D7E4D5C6E, https://asof.is/claim/clm_B65D7E4D5C6E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000025/0001551152-18-000025-index.htm.","url":"https://asof.is/claim/clm_B65D7E4D5C6E","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"3,553,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B65D7E4D5C6E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2018, filed 2018-05-04"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 69,342,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_F03C8BE56D8F, https://asof.is/claim/clm_F03C8BE56D8F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000025/0001551152-18-000025-index.htm.","url":"https://asof.is/claim/clm_F03C8BE56D8F","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"69,342,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F03C8BE56D8F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2018, filed 2018-05-04"}},{"date":"2018-04-27","until":"2018-07-31","published":"2018-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,586,879,451 shares\", as of 2018-04-27 (until 2018-07-31). Claim clm_63D489D3F6EF, https://asof.is/claim/clm_63D489D3F6EF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000025/0001551152-18-000025-index.htm.","url":"https://asof.is/claim/clm_63D489D3F6EF","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,586,879,451 shares","status":"superseded","assertable":true,"id":"clm_63D489D3F6EF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2018, filed 2018-05-04"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 61,641,000,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_01E4571FB000, https://asof.is/claim/clm_01E4571FB000, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000032/0001551152-18-000032-index.htm.","url":"https://asof.is/claim/clm_01E4571FB000","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"61,641,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_01E4571FB000","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2018, filed 2018-08-07"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 2,762,000,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_0756AC49F7F1, https://asof.is/claim/clm_0756AC49F7F1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000032/0001551152-18-000032-index.htm.","url":"https://asof.is/claim/clm_0756AC49F7F1","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"2,762,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0756AC49F7F1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2018, filed 2018-08-07"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: -3,375,000,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_3A571D375C13, https://asof.is/claim/clm_3A571D375C13, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000032/0001551152-18-000032-index.htm.","url":"https://asof.is/claim/clm_3A571D375C13","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"-3,375,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3A571D375C13","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2018, filed 2018-08-07"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 3,547,000,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_6E84A216F14F, https://asof.is/claim/clm_6E84A216F14F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000032/0001551152-18-000032-index.htm.","url":"https://asof.is/claim/clm_6E84A216F14F","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"3,547,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6E84A216F14F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2018, filed 2018-08-07"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 1,983,000,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_A3C668A4FA37, https://asof.is/claim/clm_A3C668A4FA37, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000032/0001551152-18-000032-index.htm.","url":"https://asof.is/claim/clm_A3C668A4FA37","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,983,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A3C668A4FA37","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2018, filed 2018-08-07"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 8,278,000,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_BDC07E3C1093, https://asof.is/claim/clm_BDC07E3C1093, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000032/0001551152-18-000032-index.htm.","url":"https://asof.is/claim/clm_BDC07E3C1093","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"8,278,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BDC07E3C1093","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2018, filed 2018-08-07"}},{"date":"2018-07-31","until":"2018-10-31","published":"2018-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,514,272,698 shares\", as of 2018-07-31 (until 2018-10-31). Claim clm_668466D38903, https://asof.is/claim/clm_668466D38903, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000032/0001551152-18-000032-index.htm.","url":"https://asof.is/claim/clm_668466D38903","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,514,272,698 shares","status":"superseded","assertable":true,"id":"clm_668466D38903","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2018, filed 2018-08-07"}},{"date":"2018-09-30","until":"2018-12-31","published":"2018-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 66,164,000,000 United States dollar\", as of 2018-09-30 (until 2018-12-31). Claim clm_0C6201A46264, https://asof.is/claim/clm_0C6201A46264, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000042/0001551152-18-000042-index.htm.","url":"https://asof.is/claim/clm_0C6201A46264","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"66,164,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0C6201A46264","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2018, filed 2018-11-07"}},{"date":"2018-09-30","until":"2019-03-31","published":"2018-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 3,159,000,000 United States dollar\", as of 2018-09-30 (until 2019-03-31). Claim clm_3EFA0ADA51B8, https://asof.is/claim/clm_3EFA0ADA51B8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000042/0001551152-18-000042-index.htm.","url":"https://asof.is/claim/clm_3EFA0ADA51B8","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"3,159,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3EFA0ADA51B8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2018, filed 2018-11-07"}},{"date":"2018-09-30","until":"2018-12-31","published":"2018-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 8,015,000,000 United States dollar\", as of 2018-09-30 (until 2018-12-31). Claim clm_8F6D833F6BDE, https://asof.is/claim/clm_8F6D833F6BDE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000042/0001551152-18-000042-index.htm.","url":"https://asof.is/claim/clm_8F6D833F6BDE","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"8,015,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8F6D833F6BDE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2018, filed 2018-11-07"}},{"date":"2018-09-30","until":"2019-03-31","published":"2018-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 2,747,000,000 United States dollar\", as of 2018-09-30 (until 2019-03-31). Claim clm_A401A3579B68, https://asof.is/claim/clm_A401A3579B68, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000042/0001551152-18-000042-index.htm.","url":"https://asof.is/claim/clm_A401A3579B68","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"2,747,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A401A3579B68","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2018, filed 2018-11-07"}},{"date":"2018-09-30","until":"2018-12-31","published":"2018-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: -2,921,000,000 United States dollar\", as of 2018-09-30 (until 2018-12-31). Claim clm_BEB3B81B5726, https://asof.is/claim/clm_BEB3B81B5726, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000042/0001551152-18-000042-index.htm.","url":"https://asof.is/claim/clm_BEB3B81B5726","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"-2,921,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BEB3B81B5726","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2018, filed 2018-11-07"}},{"date":"2018-09-30","until":"2019-03-31","published":"2018-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 8,236,000,000 United States dollar\", as of 2018-09-30 (until 2019-03-31). Claim clm_EF6AEA6051C0, https://asof.is/claim/clm_EF6AEA6051C0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000042/0001551152-18-000042-index.htm.","url":"https://asof.is/claim/clm_EF6AEA6051C0","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"8,236,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EF6AEA6051C0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2018, filed 2018-11-07"}},{"date":"2018-10-31","until":"2019-02-08","published":"2018-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,504,216,327 shares\", as of 2018-10-31 (until 2019-02-08). Claim clm_D17ED6882DEF, https://asof.is/claim/clm_D17ED6882DEF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000042/0001551152-18-000042-index.htm.","url":"https://asof.is/claim/clm_D17ED6882DEF","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,504,216,327 shares","status":"superseded","assertable":true,"id":"clm_D17ED6882DEF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2018, filed 2018-11-07"}},{"date":"2018-12-31","until":"2019-03-31","published":"2019-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 59,352,000,000 United States dollar\", as of 2018-12-31 (until 2019-03-31). Claim clm_50581791F51E, https://asof.is/claim/clm_50581791F51E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000008/0001551152-19-000008-index.htm.","url":"https://asof.is/claim/clm_50581791F51E","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"59,352,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_50581791F51E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2018, filed 2019-02-27"}},{"date":"2018-12-31","until":"2019-12-31","published":"2019-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie revenue: 32,753,000,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_67CC49EA52CC, https://asof.is/claim/clm_67CC49EA52CC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000008/0001551152-19-000008-index.htm.","url":"https://asof.is/claim/clm_67CC49EA52CC","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"32,753,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_67CC49EA52CC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2018, filed 2019-02-27"}},{"date":"2018-12-31","until":"2019-03-31","published":"2019-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: -8,446,000,000 United States dollar\", as of 2018-12-31 (until 2019-03-31). Claim clm_690948A561DC, https://asof.is/claim/clm_690948A561DC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000008/0001551152-19-000008-index.htm.","url":"https://asof.is/claim/clm_690948A561DC","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"-8,446,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_690948A561DC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2018, filed 2019-02-27"}},{"date":"2018-12-31","until":"2019-12-31","published":"2019-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie operating income: 6,383,000,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_C605181FAEA0, https://asof.is/claim/clm_C605181FAEA0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000008/0001551152-19-000008-index.htm.","url":"https://asof.is/claim/clm_C605181FAEA0","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"6,383,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C605181FAEA0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2018, filed 2019-02-27"}},{"date":"2018-12-31","until":"2019-03-31","published":"2019-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 7,289,000,000 United States dollar\", as of 2018-12-31 (until 2019-03-31). Claim clm_CC9157DEB0B1, https://asof.is/claim/clm_CC9157DEB0B1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000008/0001551152-19-000008-index.htm.","url":"https://asof.is/claim/clm_CC9157DEB0B1","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"7,289,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CC9157DEB0B1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2018, filed 2019-02-27"}},{"date":"2018-12-31","until":"2019-12-31","published":"2019-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie net income: 5,687,000,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_E37E3A79E8BD, https://asof.is/claim/clm_E37E3A79E8BD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000008/0001551152-19-000008-index.htm.","url":"https://asof.is/claim/clm_E37E3A79E8BD","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"5,687,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E37E3A79E8BD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2018, filed 2019-02-27"}},{"date":"2019-02-08","until":"2019-04-26","published":"2019-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,475,083,514 shares\", as of 2019-02-08 (until 2019-04-26). Claim clm_29853AC1B7D4, https://asof.is/claim/clm_29853AC1B7D4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000008/0001551152-19-000008-index.htm.","url":"https://asof.is/claim/clm_29853AC1B7D4","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,475,083,514 shares","status":"superseded","assertable":true,"id":"clm_29853AC1B7D4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2018, filed 2019-02-27"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: -7,826,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_1101E4339729, https://asof.is/claim/clm_1101E4339729, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000016/0001551152-19-000016-index.htm.","url":"https://asof.is/claim/clm_1101E4339729","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"-7,826,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1101E4339729","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2019, filed 2019-05-03"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 4,897,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_239801DFD565, https://asof.is/claim/clm_239801DFD565, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000016/0001551152-19-000016-index.htm.","url":"https://asof.is/claim/clm_239801DFD565","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"4,897,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_239801DFD565","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2019, filed 2019-05-03"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 3,010,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_2B983894BFBB, https://asof.is/claim/clm_2B983894BFBB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000016/0001551152-19-000016-index.htm.","url":"https://asof.is/claim/clm_2B983894BFBB","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"3,010,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2B983894BFBB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2019, filed 2019-05-03"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 7,828,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_7B8BB25C6DC4, https://asof.is/claim/clm_7B8BB25C6DC4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000016/0001551152-19-000016-index.htm.","url":"https://asof.is/claim/clm_7B8BB25C6DC4","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"7,828,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7B8BB25C6DC4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2019, filed 2019-05-03"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 56,769,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_9CD1CE44F2FC, https://asof.is/claim/clm_9CD1CE44F2FC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000016/0001551152-19-000016-index.htm.","url":"https://asof.is/claim/clm_9CD1CE44F2FC","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"56,769,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9CD1CE44F2FC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2019, filed 2019-05-03"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 2,456,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_A19F5E6ED2F1, https://asof.is/claim/clm_A19F5E6ED2F1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000016/0001551152-19-000016-index.htm.","url":"https://asof.is/claim/clm_A19F5E6ED2F1","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"2,456,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A19F5E6ED2F1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2019, filed 2019-05-03"}},{"date":"2019-04-26","until":"2019-07-29","published":"2019-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,478,332,177 shares\", as of 2019-04-26 (until 2019-07-29). Claim clm_F4CDCC85C327, https://asof.is/claim/clm_F4CDCC85C327, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000016/0001551152-19-000016-index.htm.","url":"https://asof.is/claim/clm_F4CDCC85C327","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,478,332,177 shares","status":"superseded","assertable":true,"id":"clm_F4CDCC85C327","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2019, filed 2019-05-03"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 57,142,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_0931D7B2DE2D, https://asof.is/claim/clm_0931D7B2DE2D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000023/0001551152-19-000023-index.htm.","url":"https://asof.is/claim/clm_0931D7B2DE2D","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"57,142,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0931D7B2DE2D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2019, filed 2019-08-05"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 8,255,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_13C8A0924EB0, https://asof.is/claim/clm_13C8A0924EB0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000023/0001551152-19-000023-index.htm.","url":"https://asof.is/claim/clm_13C8A0924EB0","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"8,255,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_13C8A0924EB0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2019, filed 2019-08-05"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 741,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_7A765E3288C2, https://asof.is/claim/clm_7A765E3288C2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000023/0001551152-19-000023-index.htm.","url":"https://asof.is/claim/clm_7A765E3288C2","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"741,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7A765E3288C2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2019, filed 2019-08-05"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: -8,566,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_8B6884305CD5, https://asof.is/claim/clm_8B6884305CD5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000023/0001551152-19-000023-index.htm.","url":"https://asof.is/claim/clm_8B6884305CD5","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"-8,566,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8B6884305CD5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2019, filed 2019-08-05"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 5,172,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_CAA6A1B515D0, https://asof.is/claim/clm_CAA6A1B515D0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000023/0001551152-19-000023-index.htm.","url":"https://asof.is/claim/clm_CAA6A1B515D0","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"5,172,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CAA6A1B515D0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2019, filed 2019-08-05"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 3,400,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_CE5BF9768804, https://asof.is/claim/clm_CE5BF9768804, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000023/0001551152-19-000023-index.htm.","url":"https://asof.is/claim/clm_CE5BF9768804","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"3,400,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CE5BF9768804","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2019, filed 2019-08-05"}},{"date":"2019-07-29","until":"2019-10-29","published":"2019-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,478,483,838 shares\", as of 2019-07-29 (until 2019-10-29). Claim clm_0A57708370A6, https://asof.is/claim/clm_0A57708370A6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000023/0001551152-19-000023-index.htm.","url":"https://asof.is/claim/clm_0A57708370A6","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,478,483,838 shares","status":"superseded","assertable":true,"id":"clm_0A57708370A6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2019, filed 2019-08-05"}},{"date":"2019-09-30","until":"2019-12-31","published":"2019-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 59,441,000,000 United States dollar\", as of 2019-09-30 (until 2019-12-31). Claim clm_2ADF32E1BBE0, https://asof.is/claim/clm_2ADF32E1BBE0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000030/0001551152-19-000030-index.htm.","url":"https://asof.is/claim/clm_2ADF32E1BBE0","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"59,441,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2ADF32E1BBE0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2019, filed 2019-11-06"}},{"date":"2019-09-30","until":"2019-12-31","published":"2019-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: -8,226,000,000 United States dollar\", as of 2019-09-30 (until 2019-12-31). Claim clm_43A1D84452B5, https://asof.is/claim/clm_43A1D84452B5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000030/0001551152-19-000030-index.htm.","url":"https://asof.is/claim/clm_43A1D84452B5","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"-8,226,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_43A1D84452B5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2019, filed 2019-11-06"}},{"date":"2019-09-30","until":"2020-03-31","published":"2019-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 1,884,000,000 United States dollar\", as of 2019-09-30 (until 2020-03-31). Claim clm_AEBAD82024FE, https://asof.is/claim/clm_AEBAD82024FE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000030/0001551152-19-000030-index.htm.","url":"https://asof.is/claim/clm_AEBAD82024FE","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,884,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AEBAD82024FE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2019, filed 2019-11-06"}},{"date":"2019-09-30","until":"2019-12-31","published":"2019-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 10,648,000,000 United States dollar\", as of 2019-09-30 (until 2019-12-31). Claim clm_B886C897B1F0, https://asof.is/claim/clm_B886C897B1F0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000030/0001551152-19-000030-index.htm.","url":"https://asof.is/claim/clm_B886C897B1F0","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"10,648,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B886C897B1F0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2019, filed 2019-11-06"}},{"date":"2019-09-30","until":"2020-03-31","published":"2019-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 8,479,000,000 United States dollar\", as of 2019-09-30 (until 2020-03-31). Claim clm_CB0B88225C13, https://asof.is/claim/clm_CB0B88225C13, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000030/0001551152-19-000030-index.htm.","url":"https://asof.is/claim/clm_CB0B88225C13","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"8,479,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CB0B88225C13","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2019, filed 2019-11-06"}},{"date":"2019-09-30","until":"2020-03-31","published":"2019-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 2,617,000,000 United States dollar\", as of 2019-09-30 (until 2020-03-31). Claim clm_F92C29C59D1E, https://asof.is/claim/clm_F92C29C59D1E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000030/0001551152-19-000030-index.htm.","url":"https://asof.is/claim/clm_F92C29C59D1E","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"2,617,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F92C29C59D1E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2019, filed 2019-11-06"}},{"date":"2019-10-29","until":"2020-01-31","published":"2019-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,478,821,109 shares\", as of 2019-10-29 (until 2020-01-31). Claim clm_3DCC4BB85B06, https://asof.is/claim/clm_3DCC4BB85B06, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000030/0001551152-19-000030-index.htm.","url":"https://asof.is/claim/clm_3DCC4BB85B06","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,478,821,109 shares","status":"superseded","assertable":true,"id":"clm_3DCC4BB85B06","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2019, filed 2019-11-06"}},{"date":"2019-12-31","until":"2020-03-31","published":"2020-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 89,115,000,000 United States dollar\", as of 2019-12-31 (until 2020-03-31). Claim clm_28B9101888C6, https://asof.is/claim/clm_28B9101888C6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000007/0001551152-20-000007-index.htm.","url":"https://asof.is/claim/clm_28B9101888C6","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"89,115,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_28B9101888C6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2019, filed 2020-02-21"}},{"date":"2019-12-31","until":"2020-03-31","published":"2020-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 39,924,000,000 United States dollar\", as of 2019-12-31 (until 2020-03-31). Claim clm_80A654D2EDD2, https://asof.is/claim/clm_80A654D2EDD2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000007/0001551152-20-000007-index.htm.","url":"https://asof.is/claim/clm_80A654D2EDD2","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"39,924,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_80A654D2EDD2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2019, filed 2020-02-21"}},{"date":"2019-12-31","until":"2020-12-31","published":"2020-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie operating income: 12,983,000,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_CDA568F800DA, https://asof.is/claim/clm_CDA568F800DA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000007/0001551152-20-000007-index.htm.","url":"https://asof.is/claim/clm_CDA568F800DA","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"12,983,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CDA568F800DA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2019, filed 2020-02-21"}},{"date":"2019-12-31","until":"2020-12-31","published":"2020-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie revenue: 33,266,000,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_EB4D7B27A2A8, https://asof.is/claim/clm_EB4D7B27A2A8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000007/0001551152-20-000007-index.htm.","url":"https://asof.is/claim/clm_EB4D7B27A2A8","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"33,266,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EB4D7B27A2A8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2019, filed 2020-02-21"}},{"date":"2019-12-31","until":"2020-03-31","published":"2020-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: -8,172,000,000 United States dollar\", as of 2019-12-31 (until 2020-03-31). Claim clm_F246E0A322BD, https://asof.is/claim/clm_F246E0A322BD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000007/0001551152-20-000007-index.htm.","url":"https://asof.is/claim/clm_F246E0A322BD","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"-8,172,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F246E0A322BD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2019, filed 2020-02-21"}},{"date":"2019-12-31","until":"2020-12-31","published":"2020-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie net income: 7,882,000,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_FB8073B6F4C9, https://asof.is/claim/clm_FB8073B6F4C9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000007/0001551152-20-000007-index.htm.","url":"https://asof.is/claim/clm_FB8073B6F4C9","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"7,882,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FB8073B6F4C9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2019, filed 2020-02-21"}},{"date":"2020-01-31","until":"2020-04-30","published":"2020-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,479,156,683 shares\", as of 2020-01-31 (until 2020-04-30). Claim clm_8A7E2D59A0AB, https://asof.is/claim/clm_8A7E2D59A0AB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000007/0001551152-20-000007-index.htm.","url":"https://asof.is/claim/clm_8A7E2D59A0AB","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,479,156,683 shares","status":"superseded","assertable":true,"id":"clm_8A7E2D59A0AB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2019, filed 2020-02-21"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 3,603,000,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_0B42818A10CA, https://asof.is/claim/clm_0B42818A10CA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000015/0001551152-20-000015-index.htm.","url":"https://asof.is/claim/clm_0B42818A10CA","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"3,603,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0B42818A10CA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2020, filed 2020-05-08"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 41,142,000,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_39876A48A684, https://asof.is/claim/clm_39876A48A684, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000015/0001551152-20-000015-index.htm.","url":"https://asof.is/claim/clm_39876A48A684","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"41,142,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_39876A48A684","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2020, filed 2020-05-08"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: -7,415,000,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_4A83CCDD28BD, https://asof.is/claim/clm_4A83CCDD28BD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000015/0001551152-20-000015-index.htm.","url":"https://asof.is/claim/clm_4A83CCDD28BD","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"-7,415,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4A83CCDD28BD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2020, filed 2020-05-08"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 91,199,000,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_9EF733A037E6, https://asof.is/claim/clm_9EF733A037E6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000015/0001551152-20-000015-index.htm.","url":"https://asof.is/claim/clm_9EF733A037E6","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"91,199,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9EF733A037E6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2020, filed 2020-05-08"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 8,619,000,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_A47008E5C136, https://asof.is/claim/clm_A47008E5C136, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000015/0001551152-20-000015-index.htm.","url":"https://asof.is/claim/clm_A47008E5C136","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"8,619,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A47008E5C136","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2020, filed 2020-05-08"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 3,010,000,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_D228AC43E824, https://asof.is/claim/clm_D228AC43E824, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000015/0001551152-20-000015-index.htm.","url":"https://asof.is/claim/clm_D228AC43E824","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"3,010,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D228AC43E824","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2020, filed 2020-05-08"}},{"date":"2020-04-30","until":"2020-07-28","published":"2020-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,476,742,215 shares\", as of 2020-04-30 (until 2020-07-28). Claim clm_6FF261038A02, https://asof.is/claim/clm_6FF261038A02, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000015/0001551152-20-000015-index.htm.","url":"https://asof.is/claim/clm_6FF261038A02","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,476,742,215 shares","status":"superseded","assertable":true,"id":"clm_6FF261038A02","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2020, filed 2020-05-08"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 149,530,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_11536613CE39, https://asof.is/claim/clm_11536613CE39, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000023/0001551152-20-000023-index.htm.","url":"https://asof.is/claim/clm_11536613CE39","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"149,530,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_11536613CE39","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2020, filed 2020-08-04"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 10,425,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_1FA32CF37088, https://asof.is/claim/clm_1FA32CF37088, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000023/0001551152-20-000023-index.htm.","url":"https://asof.is/claim/clm_1FA32CF37088","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"10,425,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1FA32CF37088","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2020, filed 2020-08-04"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: -738,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_22AD188AF61F, https://asof.is/claim/clm_22AD188AF61F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000023/0001551152-20-000023-index.htm.","url":"https://asof.is/claim/clm_22AD188AF61F","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"-738,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_22AD188AF61F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2020, filed 2020-08-04"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 14,708,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_A4BBA0E13EE6, https://asof.is/claim/clm_A4BBA0E13EE6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000023/0001551152-20-000023-index.htm.","url":"https://asof.is/claim/clm_A4BBA0E13EE6","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"14,708,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A4BBA0E13EE6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2020, filed 2020-08-04"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 6,017,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_BBD4856469BA, https://asof.is/claim/clm_BBD4856469BA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000023/0001551152-20-000023-index.htm.","url":"https://asof.is/claim/clm_BBD4856469BA","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"6,017,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BBD4856469BA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2020, filed 2020-08-04"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 752,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_DDFC85B63FE4, https://asof.is/claim/clm_DDFC85B63FE4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000023/0001551152-20-000023-index.htm.","url":"https://asof.is/claim/clm_DDFC85B63FE4","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"752,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DDFC85B63FE4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2020, filed 2020-08-04"}},{"date":"2020-07-28","until":"2020-10-27","published":"2020-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,764,833,246 shares\", as of 2020-07-28 (until 2020-10-27). Claim clm_BBC4CE8C1A41, https://asof.is/claim/clm_BBC4CE8C1A41, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000023/0001551152-20-000023-index.htm.","url":"https://asof.is/claim/clm_BBC4CE8C1A41","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,764,833,246 shares","status":"superseded","assertable":true,"id":"clm_BBC4CE8C1A41","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2020, filed 2020-08-04"}},{"date":"2020-09-30","until":"2020-12-31","published":"2020-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 15,270,000,000 United States dollar\", as of 2020-09-30 (until 2020-12-31). Claim clm_30B4D4FDA112, https://asof.is/claim/clm_30B4D4FDA112, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000032/0001551152-20-000032-index.htm.","url":"https://asof.is/claim/clm_30B4D4FDA112","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"15,270,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_30B4D4FDA112","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2020, filed 2020-11-04"}},{"date":"2020-09-30","until":"2020-12-31","published":"2020-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 149,621,000,000 United States dollar\", as of 2020-09-30 (until 2020-12-31). Claim clm_5B5F473DED16, https://asof.is/claim/clm_5B5F473DED16, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000032/0001551152-20-000032-index.htm.","url":"https://asof.is/claim/clm_5B5F473DED16","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"149,621,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5B5F473DED16","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2020, filed 2020-11-04"}},{"date":"2020-09-30","until":"2021-03-31","published":"2020-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 12,902,000,000 United States dollar\", as of 2020-09-30 (until 2021-03-31). Claim clm_91BA7A736154, https://asof.is/claim/clm_91BA7A736154, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000032/0001551152-20-000032-index.htm.","url":"https://asof.is/claim/clm_91BA7A736154","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"12,902,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_91BA7A736154","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2020, filed 2020-11-04"}},{"date":"2020-09-30","until":"2021-03-31","published":"2020-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 2,308,000,000 United States dollar\", as of 2020-09-30 (until 2021-03-31). Claim clm_AB85F916C6BF, https://asof.is/claim/clm_AB85F916C6BF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000032/0001551152-20-000032-index.htm.","url":"https://asof.is/claim/clm_AB85F916C6BF","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"2,308,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AB85F916C6BF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2020, filed 2020-11-04"}},{"date":"2020-09-30","until":"2020-12-31","published":"2020-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 7,890,000,000 United States dollar\", as of 2020-09-30 (until 2020-12-31). Claim clm_B9988D4C4506, https://asof.is/claim/clm_B9988D4C4506, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000032/0001551152-20-000032-index.htm.","url":"https://asof.is/claim/clm_B9988D4C4506","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"7,890,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B9988D4C4506","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2020, filed 2020-11-04"}},{"date":"2020-09-30","until":"2021-03-31","published":"2020-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 3,255,000,000 United States dollar\", as of 2020-09-30 (until 2021-03-31). Claim clm_DD94E377758D, https://asof.is/claim/clm_DD94E377758D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000032/0001551152-20-000032-index.htm.","url":"https://asof.is/claim/clm_DD94E377758D","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"3,255,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DD94E377758D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2020, filed 2020-11-04"}},{"date":"2020-10-27","until":"2021-01-31","published":"2020-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,765,473,923 shares\", as of 2020-10-27 (until 2021-01-31). Claim clm_D979467F30C4, https://asof.is/claim/clm_D979467F30C4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000032/0001551152-20-000032-index.htm.","url":"https://asof.is/claim/clm_D979467F30C4","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,765,473,923 shares","status":"superseded","assertable":true,"id":"clm_D979467F30C4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2020, filed 2020-11-04"}},{"date":"2020-12-31","until":"2021-12-31","published":"2021-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie net income: 4,616,000,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_0EF09B7EC590, https://asof.is/claim/clm_0EF09B7EC590, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000008/0001551152-21-000008-index.htm.","url":"https://asof.is/claim/clm_0EF09B7EC590","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"4,616,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0EF09B7EC590","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2020, filed 2021-02-19"}},{"date":"2020-12-31","until":"2021-12-31","published":"2021-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie revenue: 45,804,000,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_34A920A5AE6F, https://asof.is/claim/clm_34A920A5AE6F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000008/0001551152-21-000008-index.htm.","url":"https://asof.is/claim/clm_34A920A5AE6F","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"45,804,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_34A920A5AE6F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2020, filed 2021-02-19"}},{"date":"2020-12-31","until":"2021-03-31","published":"2021-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 8,449,000,000 United States dollar\", as of 2020-12-31 (until 2021-03-31). Claim clm_386994D20FBA, https://asof.is/claim/clm_386994D20FBA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000008/0001551152-21-000008-index.htm.","url":"https://asof.is/claim/clm_386994D20FBA","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"8,449,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_386994D20FBA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2020, filed 2021-02-19"}},{"date":"2020-12-31","until":"2021-03-31","published":"2021-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 150,565,000,000 United States dollar\", as of 2020-12-31 (until 2021-03-31). Claim clm_6E0C0CFE3683, https://asof.is/claim/clm_6E0C0CFE3683, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000008/0001551152-21-000008-index.htm.","url":"https://asof.is/claim/clm_6E0C0CFE3683","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"150,565,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6E0C0CFE3683","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2020, filed 2021-02-19"}},{"date":"2020-12-31","until":"2021-12-31","published":"2021-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie operating income: 11,363,000,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_741BF6260BB0, https://asof.is/claim/clm_741BF6260BB0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000008/0001551152-21-000008-index.htm.","url":"https://asof.is/claim/clm_741BF6260BB0","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"11,363,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_741BF6260BB0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2020, filed 2021-02-19"}},{"date":"2020-12-31","until":"2021-03-31","published":"2021-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 13,076,000,000 United States dollar\", as of 2020-12-31 (until 2021-03-31). Claim clm_B93B782FADFB, https://asof.is/claim/clm_B93B782FADFB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000008/0001551152-21-000008-index.htm.","url":"https://asof.is/claim/clm_B93B782FADFB","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"13,076,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B93B782FADFB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2020, filed 2021-02-19"}},{"date":"2021-01-31","until":"2021-04-28","published":"2021-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,765,881,690 shares\", as of 2021-01-31 (until 2021-04-28). Claim clm_2867617AC03A, https://asof.is/claim/clm_2867617AC03A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000008/0001551152-21-000008-index.htm.","url":"https://asof.is/claim/clm_2867617AC03A","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,765,881,690 shares","status":"superseded","assertable":true,"id":"clm_2867617AC03A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2020, filed 2021-02-19"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 13,010,000,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_0285E2C1A7E7, https://asof.is/claim/clm_0285E2C1A7E7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000016/0001551152-21-000016-index.htm.","url":"https://asof.is/claim/clm_0285E2C1A7E7","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"13,010,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0285E2C1A7E7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2021, filed 2021-05-07"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 4,103,000,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_5F0F6A2FD1C5, https://asof.is/claim/clm_5F0F6A2FD1C5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000016/0001551152-21-000016-index.htm.","url":"https://asof.is/claim/clm_5F0F6A2FD1C5","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"4,103,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5F0F6A2FD1C5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2021, filed 2021-05-07"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 3,553,000,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_712B18F8C713, https://asof.is/claim/clm_712B18F8C713, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000016/0001551152-21-000016-index.htm.","url":"https://asof.is/claim/clm_712B18F8C713","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"3,553,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_712B18F8C713","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2021, filed 2021-05-07"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 13,710,000,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_875E4AB51928, https://asof.is/claim/clm_875E4AB51928, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000016/0001551152-21-000016-index.htm.","url":"https://asof.is/claim/clm_875E4AB51928","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"13,710,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_875E4AB51928","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2021, filed 2021-05-07"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 9,755,000,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_87EEBCE86395, https://asof.is/claim/clm_87EEBCE86395, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000016/0001551152-21-000016-index.htm.","url":"https://asof.is/claim/clm_87EEBCE86395","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"9,755,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_87EEBCE86395","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2021, filed 2021-05-07"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 150,501,000,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_9715BC353D4D, https://asof.is/claim/clm_9715BC353D4D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000016/0001551152-21-000016-index.htm.","url":"https://asof.is/claim/clm_9715BC353D4D","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"150,501,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9715BC353D4D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2021, filed 2021-05-07"}},{"date":"2021-04-28","until":"2021-07-26","published":"2021-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,766,222,336 shares\", as of 2021-04-28 (until 2021-07-26). Claim clm_1D9411A9C895, https://asof.is/claim/clm_1D9411A9C895, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000016/0001551152-21-000016-index.htm.","url":"https://asof.is/claim/clm_1D9411A9C895","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,766,222,336 shares","status":"superseded","assertable":true,"id":"clm_1D9411A9C895","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2021, filed 2021-05-07"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 13,959,000,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_5F5081E18D14, https://asof.is/claim/clm_5F5081E18D14, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000025/0001551152-21-000025-index.htm.","url":"https://asof.is/claim/clm_5F5081E18D14","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"13,959,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5F5081E18D14","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2021, filed 2021-08-02"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 4,441,000,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_76F20660B779, https://asof.is/claim/clm_76F20660B779, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000025/0001551152-21-000025-index.htm.","url":"https://asof.is/claim/clm_76F20660B779","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"4,441,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_76F20660B779","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2021, filed 2021-08-02"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 766,000,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_8C62E1009F26, https://asof.is/claim/clm_8C62E1009F26, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000025/0001551152-21-000025-index.htm.","url":"https://asof.is/claim/clm_8C62E1009F26","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"766,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8C62E1009F26","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2021, filed 2021-08-02"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 147,972,000,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_9166925B80EB, https://asof.is/claim/clm_9166925B80EB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000025/0001551152-21-000025-index.htm.","url":"https://asof.is/claim/clm_9166925B80EB","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"147,972,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9166925B80EB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2021, filed 2021-08-02"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 8,546,000,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_A85CBBB42CDA, https://asof.is/claim/clm_A85CBBB42CDA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000025/0001551152-21-000025-index.htm.","url":"https://asof.is/claim/clm_A85CBBB42CDA","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"8,546,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A85CBBB42CDA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2021, filed 2021-08-02"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 12,569,000,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_EEA6EF5889A9, https://asof.is/claim/clm_EEA6EF5889A9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000025/0001551152-21-000025-index.htm.","url":"https://asof.is/claim/clm_EEA6EF5889A9","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"12,569,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EEA6EF5889A9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2021, filed 2021-08-02"}},{"date":"2021-07-26","until":"2021-10-25","published":"2021-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,767,175,532 shares\", as of 2021-07-26 (until 2021-10-25). Claim clm_C6A9C2ACDF37, https://asof.is/claim/clm_C6A9C2ACDF37, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000025/0001551152-21-000025-index.htm.","url":"https://asof.is/claim/clm_C6A9C2ACDF37","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,767,175,532 shares","status":"superseded","assertable":true,"id":"clm_C6A9C2ACDF37","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2021, filed 2021-08-02"}},{"date":"2021-09-30","until":"2021-12-31","published":"2021-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 148,858,000,000 United States dollar\", as of 2021-09-30 (until 2021-12-31). Claim clm_40C5FA2D2E2F, https://asof.is/claim/clm_40C5FA2D2E2F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000031/0001551152-21-000031-index.htm.","url":"https://asof.is/claim/clm_40C5FA2D2E2F","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"148,858,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_40C5FA2D2E2F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2021, filed 2021-11-02"}},{"date":"2021-09-30","until":"2022-03-31","published":"2021-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 14,342,000,000 United States dollar\", as of 2021-09-30 (until 2022-03-31). Claim clm_7EFD9B1EE312, https://asof.is/claim/clm_7EFD9B1EE312, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000031/0001551152-21-000031-index.htm.","url":"https://asof.is/claim/clm_7EFD9B1EE312","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"14,342,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7EFD9B1EE312","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2021, filed 2021-11-02"}},{"date":"2021-09-30","until":"2021-12-31","published":"2021-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 12,182,000,000 United States dollar\", as of 2021-09-30 (until 2021-12-31). Claim clm_90B6D4FB71C7, https://asof.is/claim/clm_90B6D4FB71C7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000031/0001551152-21-000031-index.htm.","url":"https://asof.is/claim/clm_90B6D4FB71C7","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"12,182,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_90B6D4FB71C7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2021, filed 2021-11-02"}},{"date":"2021-09-30","until":"2022-03-31","published":"2021-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 4,306,000,000 United States dollar\", as of 2021-09-30 (until 2022-03-31). Claim clm_A6866F9C10EF, https://asof.is/claim/clm_A6866F9C10EF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000031/0001551152-21-000031-index.htm.","url":"https://asof.is/claim/clm_A6866F9C10EF","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"4,306,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A6866F9C10EF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2021, filed 2021-11-02"}},{"date":"2021-09-30","until":"2022-03-31","published":"2021-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 3,179,000,000 United States dollar\", as of 2021-09-30 (until 2022-03-31). Claim clm_B36E746D71D8, https://asof.is/claim/clm_B36E746D71D8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000031/0001551152-21-000031-index.htm.","url":"https://asof.is/claim/clm_B36E746D71D8","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"3,179,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B36E746D71D8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2021, filed 2021-11-02"}},{"date":"2021-09-30","until":"2021-12-31","published":"2021-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 13,550,000,000 United States dollar\", as of 2021-09-30 (until 2021-12-31). Claim clm_B8F0FB3F70F4, https://asof.is/claim/clm_B8F0FB3F70F4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000031/0001551152-21-000031-index.htm.","url":"https://asof.is/claim/clm_B8F0FB3F70F4","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"13,550,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B8F0FB3F70F4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2021, filed 2021-11-02"}},{"date":"2021-10-25","until":"2022-01-31","published":"2021-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,767,880,465 shares\", as of 2021-10-25 (until 2022-01-31). Claim clm_030FB734CC46, https://asof.is/claim/clm_030FB734CC46, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000031/0001551152-21-000031-index.htm.","url":"https://asof.is/claim/clm_030FB734CC46","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,767,880,465 shares","status":"superseded","assertable":true,"id":"clm_030FB734CC46","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2021, filed 2021-11-02"}},{"date":"2021-12-31","until":"2022-12-31","published":"2022-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie operating income: 17,924,000,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_312A48E2B5D0, https://asof.is/claim/clm_312A48E2B5D0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000007/0001551152-22-000007-index.htm.","url":"https://asof.is/claim/clm_312A48E2B5D0","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"17,924,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_312A48E2B5D0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2021, filed 2022-02-18"}},{"date":"2021-12-31","until":"2022-12-31","published":"2022-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie net income: 11,542,000,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_37B2CAD3C6F1, https://asof.is/claim/clm_37B2CAD3C6F1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000007/0001551152-22-000007-index.htm.","url":"https://asof.is/claim/clm_37B2CAD3C6F1","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"11,542,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_37B2CAD3C6F1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2021, filed 2022-02-18"}},{"date":"2021-12-31","until":"2022-03-31","published":"2022-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 146,529,000,000 United States dollar\", as of 2021-12-31 (until 2022-03-31). Claim clm_5711E0284444, https://asof.is/claim/clm_5711E0284444, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000007/0001551152-22-000007-index.htm.","url":"https://asof.is/claim/clm_5711E0284444","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"146,529,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5711E0284444","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2021, filed 2022-02-18"}},{"date":"2021-12-31","until":"2022-03-31","published":"2022-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 9,746,000,000 United States dollar\", as of 2021-12-31 (until 2022-03-31). Claim clm_A2ED4BA1F89D, https://asof.is/claim/clm_A2ED4BA1F89D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000007/0001551152-22-000007-index.htm.","url":"https://asof.is/claim/clm_A2ED4BA1F89D","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"9,746,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A2ED4BA1F89D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2021, filed 2022-02-18"}},{"date":"2021-12-31","until":"2022-03-31","published":"2022-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 15,408,000,000 United States dollar\", as of 2021-12-31 (until 2022-03-31). Claim clm_B2E8F0E008D0, https://asof.is/claim/clm_B2E8F0E008D0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000007/0001551152-22-000007-index.htm.","url":"https://asof.is/claim/clm_B2E8F0E008D0","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"15,408,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B2E8F0E008D0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2021, filed 2022-02-18"}},{"date":"2021-12-31","until":"2022-12-31","published":"2022-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie revenue: 56,197,000,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_D102FEEF7A89, https://asof.is/claim/clm_D102FEEF7A89, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000007/0001551152-22-000007-index.htm.","url":"https://asof.is/claim/clm_D102FEEF7A89","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"56,197,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D102FEEF7A89","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2021, filed 2022-02-18"}},{"date":"2022-01-31","until":"2022-04-27","published":"2022-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,768,753,829 shares\", as of 2022-01-31 (until 2022-04-27). Claim clm_DF17B249782C, https://asof.is/claim/clm_DF17B249782C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000007/0001551152-22-000007-index.htm.","url":"https://asof.is/claim/clm_DF17B249782C","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,768,753,829 shares","status":"superseded","assertable":true,"id":"clm_DF17B249782C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2021, filed 2022-02-18"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 13,538,000,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_020CA528788D, https://asof.is/claim/clm_020CA528788D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000017/0001551152-22-000017-index.htm.","url":"https://asof.is/claim/clm_020CA528788D","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"13,538,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_020CA528788D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2022, filed 2022-05-06"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 4,490,000,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_0A98B6612119, https://asof.is/claim/clm_0A98B6612119, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000017/0001551152-22-000017-index.htm.","url":"https://asof.is/claim/clm_0A98B6612119","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"4,490,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0A98B6612119","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2022, filed 2022-05-06"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 16,283,000,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_55D207F88E40, https://asof.is/claim/clm_55D207F88E40, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000017/0001551152-22-000017-index.htm.","url":"https://asof.is/claim/clm_55D207F88E40","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"16,283,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_55D207F88E40","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2022, filed 2022-05-06"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 4,717,000,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_68DCF1A8E9E3, https://asof.is/claim/clm_68DCF1A8E9E3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000017/0001551152-22-000017-index.htm.","url":"https://asof.is/claim/clm_68DCF1A8E9E3","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"4,717,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_68DCF1A8E9E3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2022, filed 2022-05-06"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 143,211,000,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_988B5ED6F448, https://asof.is/claim/clm_988B5ED6F448, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000017/0001551152-22-000017-index.htm.","url":"https://asof.is/claim/clm_988B5ED6F448","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"143,211,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_988B5ED6F448","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2022, filed 2022-05-06"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 6,098,000,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_C8B5152DE66D, https://asof.is/claim/clm_C8B5152DE66D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000017/0001551152-22-000017-index.htm.","url":"https://asof.is/claim/clm_C8B5152DE66D","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"6,098,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C8B5152DE66D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2022, filed 2022-05-06"}},{"date":"2022-04-27","until":"2022-07-27","published":"2022-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,767,110,083 shares\", as of 2022-04-27 (until 2022-07-27). Claim clm_8956DD97BC9C, https://asof.is/claim/clm_8956DD97BC9C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000017/0001551152-22-000017-index.htm.","url":"https://asof.is/claim/clm_8956DD97BC9C","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,767,110,083 shares","status":"superseded","assertable":true,"id":"clm_8956DD97BC9C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2022, filed 2022-05-06"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 143,186,000,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_1C492364766C, https://asof.is/claim/clm_1C492364766C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000030/0001551152-22-000030-index.htm.","url":"https://asof.is/claim/clm_1C492364766C","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"143,186,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1C492364766C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2022, filed 2022-08-04"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 14,653,000,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_3DA39727C116, https://asof.is/claim/clm_3DA39727C116, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000030/0001551152-22-000030-index.htm.","url":"https://asof.is/claim/clm_3DA39727C116","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"14,653,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3DA39727C116","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2022, filed 2022-08-04"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 3,295,000,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_9573F19B5964, https://asof.is/claim/clm_9573F19B5964, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000030/0001551152-22-000030-index.htm.","url":"https://asof.is/claim/clm_9573F19B5964","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"3,295,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9573F19B5964","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2022, filed 2022-08-04"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 924,000,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_D086E009B1C1, https://asof.is/claim/clm_D086E009B1C1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000030/0001551152-22-000030-index.htm.","url":"https://asof.is/claim/clm_D086E009B1C1","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"924,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D086E009B1C1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2022, filed 2022-08-04"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 8,521,000,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_D466A4BBCCE0, https://asof.is/claim/clm_D466A4BBCCE0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000030/0001551152-22-000030-index.htm.","url":"https://asof.is/claim/clm_D466A4BBCCE0","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"8,521,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D466A4BBCCE0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2022, filed 2022-08-04"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 14,583,000,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_FC05FDDBEA11, https://asof.is/claim/clm_FC05FDDBEA11, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000030/0001551152-22-000030-index.htm.","url":"https://asof.is/claim/clm_FC05FDDBEA11","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"14,583,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FC05FDDBEA11","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2022, filed 2022-08-04"}},{"date":"2022-07-27","until":"2022-10-26","published":"2022-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,768,096,495 shares\", as of 2022-07-27 (until 2022-10-26). Claim clm_20CB053D8AED, https://asof.is/claim/clm_20CB053D8AED, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000030/0001551152-22-000030-index.htm.","url":"https://asof.is/claim/clm_20CB053D8AED","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,768,096,495 shares","status":"superseded","assertable":true,"id":"clm_20CB053D8AED","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2022, filed 2022-08-04"}},{"date":"2022-09-30","until":"2023-03-31","published":"2022-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 3,949,000,000 United States dollar\", as of 2022-09-30 (until 2023-03-31). Claim clm_16B89E250F5D, https://asof.is/claim/clm_16B89E250F5D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000045/0001551152-22-000045-index.htm.","url":"https://asof.is/claim/clm_16B89E250F5D","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"3,949,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_16B89E250F5D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2022, filed 2022-11-04"}},{"date":"2022-09-30","until":"2023-03-31","published":"2022-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 14,812,000,000 United States dollar\", as of 2022-09-30 (until 2023-03-31). Claim clm_180AA5A76ED5, https://asof.is/claim/clm_180AA5A76ED5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000045/0001551152-22-000045-index.htm.","url":"https://asof.is/claim/clm_180AA5A76ED5","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"14,812,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_180AA5A76ED5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2022, filed 2022-11-04"}},{"date":"2022-09-30","until":"2022-12-31","published":"2022-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 141,325,000,000 United States dollar\", as of 2022-09-30 (until 2022-12-31). Claim clm_191A92225E47, https://asof.is/claim/clm_191A92225E47, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000045/0001551152-22-000045-index.htm.","url":"https://asof.is/claim/clm_191A92225E47","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"141,325,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_191A92225E47","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2022, filed 2022-11-04"}},{"date":"2022-09-30","until":"2022-12-31","published":"2022-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 11,832,000,000 United States dollar\", as of 2022-09-30 (until 2022-12-31). Claim clm_C88762AEF762, https://asof.is/claim/clm_C88762AEF762, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000045/0001551152-22-000045-index.htm.","url":"https://asof.is/claim/clm_C88762AEF762","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"11,832,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C88762AEF762","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2022, filed 2022-11-04"}},{"date":"2022-09-30","until":"2023-03-31","published":"2022-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 4,603,000,000 United States dollar\", as of 2022-09-30 (until 2023-03-31). Claim clm_CEA4039DB60E, https://asof.is/claim/clm_CEA4039DB60E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000045/0001551152-22-000045-index.htm.","url":"https://asof.is/claim/clm_CEA4039DB60E","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"4,603,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CEA4039DB60E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2022, filed 2022-11-04"}},{"date":"2022-09-30","until":"2022-12-31","published":"2022-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 15,994,000,000 United States dollar\", as of 2022-09-30 (until 2022-12-31). Claim clm_D0C776D4C6FD, https://asof.is/claim/clm_D0C776D4C6FD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000045/0001551152-22-000045-index.htm.","url":"https://asof.is/claim/clm_D0C776D4C6FD","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"15,994,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D0C776D4C6FD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2022, filed 2022-11-04"}},{"date":"2022-10-26","until":"2023-01-31","published":"2022-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,768,480,508 shares\", as of 2022-10-26 (until 2023-01-31). Claim clm_056C1FAF9A19, https://asof.is/claim/clm_056C1FAF9A19, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000045/0001551152-22-000045-index.htm.","url":"https://asof.is/claim/clm_056C1FAF9A19","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,768,480,508 shares","status":"superseded","assertable":true,"id":"clm_056C1FAF9A19","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2022, filed 2022-11-04"}},{"date":"2022-12-31","until":"2023-03-31","published":"2023-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 17,254,000,000 United States dollar\", as of 2022-12-31 (until 2023-03-31). Claim clm_79A5901E7AEB, https://asof.is/claim/clm_79A5901E7AEB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000011/0001551152-23-000011-index.htm.","url":"https://asof.is/claim/clm_79A5901E7AEB","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"17,254,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_79A5901E7AEB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2022, filed 2023-02-17"}},{"date":"2022-12-31","until":"2023-12-31","published":"2023-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie operating income: 18,117,000,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_810E9C4E1BC6, https://asof.is/claim/clm_810E9C4E1BC6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000011/0001551152-23-000011-index.htm.","url":"https://asof.is/claim/clm_810E9C4E1BC6","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"18,117,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_810E9C4E1BC6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2022, filed 2023-02-17"}},{"date":"2022-12-31","until":"2023-03-31","published":"2023-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 138,805,000,000 United States dollar\", as of 2022-12-31 (until 2023-03-31). Claim clm_8F94B2DED299, https://asof.is/claim/clm_8F94B2DED299, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000011/0001551152-23-000011-index.htm.","url":"https://asof.is/claim/clm_8F94B2DED299","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"138,805,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8F94B2DED299","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2022, filed 2023-02-17"}},{"date":"2022-12-31","until":"2023-03-31","published":"2023-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 9,201,000,000 United States dollar\", as of 2022-12-31 (until 2023-03-31). Claim clm_9196480FD2FF, https://asof.is/claim/clm_9196480FD2FF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000011/0001551152-23-000011-index.htm.","url":"https://asof.is/claim/clm_9196480FD2FF","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"9,201,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9196480FD2FF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2022, filed 2023-02-17"}},{"date":"2022-12-31","until":"2023-12-31","published":"2023-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie revenue: 58,054,000,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_C6FBA5E61236, https://asof.is/claim/clm_C6FBA5E61236, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000011/0001551152-23-000011-index.htm.","url":"https://asof.is/claim/clm_C6FBA5E61236","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"58,054,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C6FBA5E61236","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2022, filed 2023-02-17"}},{"date":"2022-12-31","until":"2023-12-31","published":"2023-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie net income: 11,836,000,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_DEF5E95E0C29, https://asof.is/claim/clm_DEF5E95E0C29, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000011/0001551152-23-000011-index.htm.","url":"https://asof.is/claim/clm_DEF5E95E0C29","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"11,836,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DEF5E95E0C29","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2022, filed 2023-02-17"}},{"date":"2023-01-31","until":"2023-04-25","published":"2023-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,769,399,971 shares\", as of 2023-01-31 (until 2023-04-25). Claim clm_E2538BAC615B, https://asof.is/claim/clm_E2538BAC615B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000011/0001551152-23-000011-index.htm.","url":"https://asof.is/claim/clm_E2538BAC615B","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,769,399,971 shares","status":"superseded","assertable":true,"id":"clm_E2538BAC615B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2022, filed 2023-02-17"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 134,544,000,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_456ABC3AB1E9, https://asof.is/claim/clm_456ABC3AB1E9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000023/0001551152-23-000023-index.htm.","url":"https://asof.is/claim/clm_456ABC3AB1E9","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"134,544,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_456ABC3AB1E9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2023, filed 2023-05-05"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 239,000,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_78FB737BE749, https://asof.is/claim/clm_78FB737BE749, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000023/0001551152-23-000023-index.htm.","url":"https://asof.is/claim/clm_78FB737BE749","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"239,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_78FB737BE749","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2023, filed 2023-05-05"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 13,274,000,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_A6146EA9ECE9, https://asof.is/claim/clm_A6146EA9ECE9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000023/0001551152-23-000023-index.htm.","url":"https://asof.is/claim/clm_A6146EA9ECE9","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"13,274,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A6146EA9ECE9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2023, filed 2023-05-05"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 2,768,000,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_C0D9B2A2E414, https://asof.is/claim/clm_C0D9B2A2E414, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000023/0001551152-23-000023-index.htm.","url":"https://asof.is/claim/clm_C0D9B2A2E414","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"2,768,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C0D9B2A2E414","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2023, filed 2023-05-05"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 12,225,000,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_CBFCA4B48C56, https://asof.is/claim/clm_CBFCA4B48C56, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000023/0001551152-23-000023-index.htm.","url":"https://asof.is/claim/clm_CBFCA4B48C56","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"12,225,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CBFCA4B48C56","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2023, filed 2023-05-05"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 6,711,000,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_D0F44FB1629D, https://asof.is/claim/clm_D0F44FB1629D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000023/0001551152-23-000023-index.htm.","url":"https://asof.is/claim/clm_D0F44FB1629D","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"6,711,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D0F44FB1629D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2023, filed 2023-05-05"}},{"date":"2023-04-25","until":"2023-07-31","published":"2023-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,764,289,680 shares\", as of 2023-04-25 (until 2023-07-31). Claim clm_10DDA59C62B6, https://asof.is/claim/clm_10DDA59C62B6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000023/0001551152-23-000023-index.htm.","url":"https://asof.is/claim/clm_10DDA59C62B6","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,764,289,680 shares","status":"superseded","assertable":true,"id":"clm_10DDA59C62B6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2023, filed 2023-05-05"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 135,367,000,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_55D254B2AB25, https://asof.is/claim/clm_55D254B2AB25, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000033/0001551152-23-000033-index.htm.","url":"https://asof.is/claim/clm_55D254B2AB25","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"135,367,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_55D254B2AB25","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2023, filed 2023-08-07"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 13,865,000,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_593BEB422FF1, https://asof.is/claim/clm_593BEB422FF1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000033/0001551152-23-000033-index.htm.","url":"https://asof.is/claim/clm_593BEB422FF1","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"13,865,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_593BEB422FF1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2023, filed 2023-08-07"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 2,024,000,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_5E66D98A66E7, https://asof.is/claim/clm_5E66D98A66E7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000033/0001551152-23-000033-index.htm.","url":"https://asof.is/claim/clm_5E66D98A66E7","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"2,024,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5E66D98A66E7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2023, filed 2023-08-07"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 12,866,000,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_D0CAEDA52B47, https://asof.is/claim/clm_D0CAEDA52B47, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000033/0001551152-23-000033-index.htm.","url":"https://asof.is/claim/clm_D0CAEDA52B47","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"12,866,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D0CAEDA52B47","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2023, filed 2023-08-07"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 8,759,000,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_F77382A19536, https://asof.is/claim/clm_F77382A19536, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000033/0001551152-23-000033-index.htm.","url":"https://asof.is/claim/clm_F77382A19536","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"8,759,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F77382A19536","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2023, filed 2023-08-07"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 4,513,000,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_FD718C31F784, https://asof.is/claim/clm_FD718C31F784, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000033/0001551152-23-000033-index.htm.","url":"https://asof.is/claim/clm_FD718C31F784","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"4,513,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FD718C31F784","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2023, filed 2023-08-07"}},{"date":"2023-07-31","until":"2023-10-27","published":"2023-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,765,046,680 shares\", as of 2023-07-31 (until 2023-10-27). Claim clm_6CE3680212C4, https://asof.is/claim/clm_6CE3680212C4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000033/0001551152-23-000033-index.htm.","url":"https://asof.is/claim/clm_6CE3680212C4","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,765,046,680 shares","status":"superseded","assertable":true,"id":"clm_6CE3680212C4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2023, filed 2023-08-07"}},{"date":"2023-09-30","until":"2024-03-31","published":"2023-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 13,927,000,000 United States dollar\", as of 2023-09-30 (until 2024-03-31). Claim clm_2E4438989255, https://asof.is/claim/clm_2E4438989255, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000045/0001551152-23-000045-index.htm.","url":"https://asof.is/claim/clm_2E4438989255","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"13,927,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2E4438989255","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2023, filed 2023-11-06"}},{"date":"2023-09-30","until":"2024-03-31","published":"2023-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 1,778,000,000 United States dollar\", as of 2023-09-30 (until 2024-03-31). Claim clm_4ECAA41CE1D4, https://asof.is/claim/clm_4ECAA41CE1D4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000045/0001551152-23-000045-index.htm.","url":"https://asof.is/claim/clm_4ECAA41CE1D4","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,778,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4ECAA41CE1D4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2023, filed 2023-11-06"}},{"date":"2023-09-30","until":"2023-12-31","published":"2023-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 13,287,000,000 United States dollar\", as of 2023-09-30 (until 2023-12-31). Claim clm_8F4CF168CDB2, https://asof.is/claim/clm_8F4CF168CDB2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000045/0001551152-23-000045-index.htm.","url":"https://asof.is/claim/clm_8F4CF168CDB2","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"13,287,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8F4CF168CDB2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2023, filed 2023-11-06"}},{"date":"2023-09-30","until":"2023-12-31","published":"2023-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 136,221,000,000 United States dollar\", as of 2023-09-30 (until 2023-12-31). Claim clm_9AD5695F0536, https://asof.is/claim/clm_9AD5695F0536, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000045/0001551152-23-000045-index.htm.","url":"https://asof.is/claim/clm_9AD5695F0536","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"136,221,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9AD5695F0536","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2023, filed 2023-11-06"}},{"date":"2023-09-30","until":"2024-03-31","published":"2023-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 2,281,000,000 United States dollar\", as of 2023-09-30 (until 2024-03-31). Claim clm_A6F43E732D82, https://asof.is/claim/clm_A6F43E732D82, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000045/0001551152-23-000045-index.htm.","url":"https://asof.is/claim/clm_A6F43E732D82","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"2,281,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A6F43E732D82","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2023, filed 2023-11-06"}},{"date":"2023-09-30","until":"2023-12-31","published":"2023-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 12,094,000,000 United States dollar\", as of 2023-09-30 (until 2023-12-31). Claim clm_DA2BBA888E3B, https://asof.is/claim/clm_DA2BBA888E3B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000045/0001551152-23-000045-index.htm.","url":"https://asof.is/claim/clm_DA2BBA888E3B","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"12,094,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DA2BBA888E3B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2023, filed 2023-11-06"}},{"date":"2023-10-27","until":"2024-01-31","published":"2023-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,765,537,421 shares\", as of 2023-10-27 (until 2024-01-31). Claim clm_A6F2CE4E7D05, https://asof.is/claim/clm_A6F2CE4E7D05, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000045/0001551152-23-000045-index.htm.","url":"https://asof.is/claim/clm_A6F2CE4E7D05","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,765,537,421 shares","status":"superseded","assertable":true,"id":"clm_A6F2CE4E7D05","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2023, filed 2023-11-06"}},{"date":"2023-12-31","until":"2024-12-31","published":"2024-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie operating income: 12,757,000,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_5D66F3208260, https://asof.is/claim/clm_5D66F3208260, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000011/0001551152-24-000011-index.htm.","url":"https://asof.is/claim/clm_5D66F3208260","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"12,757,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5D66F3208260","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2023, filed 2024-02-20"}},{"date":"2023-12-31","until":"2024-03-31","published":"2024-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 10,360,000,000 United States dollar\", as of 2023-12-31 (until 2024-03-31). Claim clm_897825A51216, https://asof.is/claim/clm_897825A51216, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000011/0001551152-24-000011-index.htm.","url":"https://asof.is/claim/clm_897825A51216","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"10,360,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_897825A51216","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2023, filed 2024-02-20"}},{"date":"2023-12-31","until":"2024-12-31","published":"2024-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie net income: 4,863,000,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_89DC93530D47, https://asof.is/claim/clm_89DC93530D47, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000011/0001551152-24-000011-index.htm.","url":"https://asof.is/claim/clm_89DC93530D47","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"4,863,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_89DC93530D47","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2023, filed 2024-02-20"}},{"date":"2023-12-31","until":"2024-12-31","published":"2024-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie revenue: 54,318,000,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_94FBAE0710ED, https://asof.is/claim/clm_94FBAE0710ED, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000011/0001551152-24-000011-index.htm.","url":"https://asof.is/claim/clm_94FBAE0710ED","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"54,318,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_94FBAE0710ED","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2023, filed 2024-02-20"}},{"date":"2023-12-31","until":"2024-03-31","published":"2024-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 12,814,000,000 United States dollar\", as of 2023-12-31 (until 2024-03-31). Claim clm_D3C029303D23, https://asof.is/claim/clm_D3C029303D23, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000011/0001551152-24-000011-index.htm.","url":"https://asof.is/claim/clm_D3C029303D23","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"12,814,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D3C029303D23","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2023, filed 2024-02-20"}},{"date":"2023-12-31","until":"2024-03-31","published":"2024-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 134,711,000,000 United States dollar\", as of 2023-12-31 (until 2024-03-31). Claim clm_E2D8EC5BAEAA, https://asof.is/claim/clm_E2D8EC5BAEAA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000011/0001551152-24-000011-index.htm.","url":"https://asof.is/claim/clm_E2D8EC5BAEAA","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"134,711,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E2D8EC5BAEAA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2023, filed 2024-02-20"}},{"date":"2024-01-31","until":"2024-04-25","published":"2024-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,766,473,359 shares\", as of 2024-01-31 (until 2024-04-25). Claim clm_89944DBAFE9E, https://asof.is/claim/clm_89944DBAFE9E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000011/0001551152-24-000011-index.htm.","url":"https://asof.is/claim/clm_89944DBAFE9E","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,766,473,359 shares","status":"superseded","assertable":true,"id":"clm_89944DBAFE9E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2023, filed 2024-02-20"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 148,874,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_29497973C1B0, https://asof.is/claim/clm_29497973C1B0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000020/0001551152-24-000020-index.htm.","url":"https://asof.is/claim/clm_29497973C1B0","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"148,874,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_29497973C1B0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2024, filed 2024-05-03"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 1,369,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_5B428B1167B8, https://asof.is/claim/clm_5B428B1167B8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000020/0001551152-24-000020-index.htm.","url":"https://asof.is/claim/clm_5B428B1167B8","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,369,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5B428B1167B8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2024, filed 2024-05-03"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 18,067,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_5C0E4B389278, https://asof.is/claim/clm_5C0E4B389278, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000020/0001551152-24-000020-index.htm.","url":"https://asof.is/claim/clm_5C0E4B389278","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"18,067,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5C0E4B389278","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2024, filed 2024-05-03"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 2,798,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_854E200D3C92, https://asof.is/claim/clm_854E200D3C92, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000020/0001551152-24-000020-index.htm.","url":"https://asof.is/claim/clm_854E200D3C92","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"2,798,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_854E200D3C92","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2024, filed 2024-05-03"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 12,310,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_E449A119B758, https://asof.is/claim/clm_E449A119B758, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000020/0001551152-24-000020-index.htm.","url":"https://asof.is/claim/clm_E449A119B758","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"12,310,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E449A119B758","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2024, filed 2024-05-03"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 8,007,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_E994FFA98EDE, https://asof.is/claim/clm_E994FFA98EDE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000020/0001551152-24-000020-index.htm.","url":"https://asof.is/claim/clm_E994FFA98EDE","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"8,007,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E994FFA98EDE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2024, filed 2024-05-03"}},{"date":"2024-04-25","until":"2024-07-29","published":"2024-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,765,867,781 shares\", as of 2024-04-25 (until 2024-07-29). Claim clm_5773E4734F59, https://asof.is/claim/clm_5773E4734F59, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000020/0001551152-24-000020-index.htm.","url":"https://asof.is/claim/clm_5773E4734F59","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,765,867,781 shares","status":"superseded","assertable":true,"id":"clm_5773E4734F59","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2024, filed 2024-05-03"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 1,370,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_1CC594D9C4F0, https://asof.is/claim/clm_1CC594D9C4F0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000031/0001551152-24-000031-index.htm.","url":"https://asof.is/claim/clm_1CC594D9C4F0","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,370,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1CC594D9C4F0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2024, filed 2024-08-07"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 6,778,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_44F4EB401556, https://asof.is/claim/clm_44F4EB401556, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000031/0001551152-24-000031-index.htm.","url":"https://asof.is/claim/clm_44F4EB401556","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"6,778,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_44F4EB401556","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2024, filed 2024-08-07"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 141,937,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_4B6461184F69, https://asof.is/claim/clm_4B6461184F69, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000031/0001551152-24-000031-index.htm.","url":"https://asof.is/claim/clm_4B6461184F69","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"141,937,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4B6461184F69","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2024, filed 2024-08-07"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 14,462,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_702A9C257ED5, https://asof.is/claim/clm_702A9C257ED5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000031/0001551152-24-000031-index.htm.","url":"https://asof.is/claim/clm_702A9C257ED5","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"14,462,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_702A9C257ED5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2024, filed 2024-08-07"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 3,998,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_9B48C67E536A, https://asof.is/claim/clm_9B48C67E536A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000031/0001551152-24-000031-index.htm.","url":"https://asof.is/claim/clm_9B48C67E536A","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"3,998,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9B48C67E536A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2024, filed 2024-08-07"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 13,130,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_C708C0B4DD61, https://asof.is/claim/clm_C708C0B4DD61, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000031/0001551152-24-000031-index.htm.","url":"https://asof.is/claim/clm_C708C0B4DD61","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"13,130,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C708C0B4DD61","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2024, filed 2024-08-07"}},{"date":"2024-07-29","until":"2024-10-28","published":"2024-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,766,343,745 shares\", as of 2024-07-29 (until 2024-10-28). Claim clm_EF2804D82FE5, https://asof.is/claim/clm_EF2804D82FE5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000031/0001551152-24-000031-index.htm.","url":"https://asof.is/claim/clm_EF2804D82FE5","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,766,343,745 shares","status":"superseded","assertable":true,"id":"clm_EF2804D82FE5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2024, filed 2024-08-07"}},{"date":"2024-09-30","until":"2024-12-31","published":"2024-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 143,422,000,000 United States dollar\", as of 2024-09-30 (until 2024-12-31). Claim clm_114245DEFEF9, https://asof.is/claim/clm_114245DEFEF9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000040/0001551152-24-000040-index.htm.","url":"https://asof.is/claim/clm_114245DEFEF9","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"143,422,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_114245DEFEF9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2024, filed 2024-11-04"}},{"date":"2024-09-30","until":"2024-12-31","published":"2024-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 6,032,000,000 United States dollar\", as of 2024-09-30 (until 2024-12-31). Claim clm_15A624C68E3C, https://asof.is/claim/clm_15A624C68E3C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000040/0001551152-24-000040-index.htm.","url":"https://asof.is/claim/clm_15A624C68E3C","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"6,032,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_15A624C68E3C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2024, filed 2024-11-04"}},{"date":"2024-09-30","until":"2025-03-31","published":"2024-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 14,460,000,000 United States dollar\", as of 2024-09-30 (until 2025-03-31). Claim clm_1DE14AF1FBB3, https://asof.is/claim/clm_1DE14AF1FBB3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000040/0001551152-24-000040-index.htm.","url":"https://asof.is/claim/clm_1DE14AF1FBB3","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"14,460,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1DE14AF1FBB3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2024, filed 2024-11-04"}},{"date":"2024-09-30","until":"2025-03-31","published":"2024-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 1,561,000,000 United States dollar\", as of 2024-09-30 (until 2025-03-31). Claim clm_930D6A477C14, https://asof.is/claim/clm_930D6A477C14, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000040/0001551152-24-000040-index.htm.","url":"https://asof.is/claim/clm_930D6A477C14","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,561,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_930D6A477C14","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2024, filed 2024-11-04"}},{"date":"2024-09-30","until":"2024-12-31","published":"2024-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 7,257,000,000 United States dollar\", as of 2024-09-30 (until 2024-12-31). Claim clm_A6BEF465151C, https://asof.is/claim/clm_A6BEF465151C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000040/0001551152-24-000040-index.htm.","url":"https://asof.is/claim/clm_A6BEF465151C","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"7,257,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A6BEF465151C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2024, filed 2024-11-04"}},{"date":"2024-09-30","until":"2025-03-31","published":"2024-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 3,831,000,000 United States dollar\", as of 2024-09-30 (until 2025-03-31). Claim clm_C42D4D3906A5, https://asof.is/claim/clm_C42D4D3906A5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000040/0001551152-24-000040-index.htm.","url":"https://asof.is/claim/clm_C42D4D3906A5","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"3,831,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C42D4D3906A5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2024, filed 2024-11-04"}},{"date":"2024-10-28","until":"2025-01-31","published":"2024-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,767,140,323 shares\", as of 2024-10-28 (until 2025-01-31). Claim clm_633C3749CF8B, https://asof.is/claim/clm_633C3749CF8B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000040/0001551152-24-000040-index.htm.","url":"https://asof.is/claim/clm_633C3749CF8B","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,767,140,323 shares","status":"superseded","assertable":true,"id":"clm_633C3749CF8B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2024, filed 2024-11-04"}},{"date":"2024-12-31","until":"2025-03-31","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 135,161,000,000 United States dollar\", as of 2024-12-31 (until 2025-03-31). Claim clm_1A98128E2186, https://asof.is/claim/clm_1A98128E2186, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/0001551152-25-000020-index.htm.","url":"https://asof.is/claim/clm_1A98128E2186","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"135,161,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1A98128E2186","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2024, filed 2025-02-14"}},{"date":"2024-12-31","until":"2025-03-31","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 5,524,000,000 United States dollar\", as of 2024-12-31 (until 2025-03-31). Claim clm_42142B046C44, https://asof.is/claim/clm_42142B046C44, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/0001551152-25-000020-index.htm.","url":"https://asof.is/claim/clm_42142B046C44","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"5,524,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_42142B046C44","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2024, filed 2025-02-14"}},{"date":"2024-12-31","until":"2025-12-31","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie net income: 4,278,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_4595D4B200E2, https://asof.is/claim/clm_4595D4B200E2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/0001551152-25-000020-index.htm.","url":"https://asof.is/claim/clm_4595D4B200E2","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"4,278,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4595D4B200E2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2024, filed 2025-02-14"}},{"date":"2024-12-31","until":"2025-12-31","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie revenue: 56,334,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_46C087CADCC6, https://asof.is/claim/clm_46C087CADCC6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/0001551152-25-000020-index.htm.","url":"https://asof.is/claim/clm_46C087CADCC6","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"56,334,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_46C087CADCC6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2024, filed 2025-02-14"}},{"date":"2024-12-31","until":"2025-12-31","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie operating income: 9,137,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_7198B453007F, https://asof.is/claim/clm_7198B453007F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/0001551152-25-000020-index.htm.","url":"https://asof.is/claim/clm_7198B453007F","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"9,137,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7198B453007F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2024, filed 2025-02-14"}},{"date":"2024-12-31","until":"2025-03-31","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 3,325,000,000 United States dollar\", as of 2024-12-31 (until 2025-03-31). Claim clm_A7EA278F1A95, https://asof.is/claim/clm_A7EA278F1A95, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/0001551152-25-000020-index.htm.","url":"https://asof.is/claim/clm_A7EA278F1A95","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"3,325,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A7EA278F1A95","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2024, filed 2025-02-14"}},{"date":"2025-01-31","until":"2025-04-30","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,765,354,859 shares\", as of 2025-01-31 (until 2025-04-30). Claim clm_577B3A94C3B3, https://asof.is/claim/clm_577B3A94C3B3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/0001551152-25-000020-index.htm.","url":"https://asof.is/claim/clm_577B3A94C3B3","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,765,354,859 shares","status":"superseded","assertable":true,"id":"clm_577B3A94C3B3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2024, filed 2025-02-14"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: 1,420,000,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_1A40CEC7F75A, https://asof.is/claim/clm_1A40CEC7F75A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000029/0001551152-25-000029-index.htm.","url":"https://asof.is/claim/clm_1A40CEC7F75A","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"1,420,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1A40CEC7F75A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2025, filed 2025-05-09"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 5,175,000,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_213E56FCF1C0, https://asof.is/claim/clm_213E56FCF1C0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000029/0001551152-25-000029-index.htm.","url":"https://asof.is/claim/clm_213E56FCF1C0","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"5,175,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_213E56FCF1C0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2025, filed 2025-05-09"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 1,286,000,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_7C59982F22F4, https://asof.is/claim/clm_7C59982F22F4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000029/0001551152-25-000029-index.htm.","url":"https://asof.is/claim/clm_7C59982F22F4","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"1,286,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7C59982F22F4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2025, filed 2025-05-09"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 13,343,000,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_8213D3858DF4, https://asof.is/claim/clm_8213D3858DF4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000029/0001551152-25-000029-index.htm.","url":"https://asof.is/claim/clm_8213D3858DF4","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"13,343,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8213D3858DF4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2025, filed 2025-05-09"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 3,733,000,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_837AACDD66BC, https://asof.is/claim/clm_837AACDD66BC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000029/0001551152-25-000029-index.htm.","url":"https://asof.is/claim/clm_837AACDD66BC","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"3,733,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_837AACDD66BC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2025, filed 2025-05-09"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 136,165,000,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_E8E57D49C82F, https://asof.is/claim/clm_E8E57D49C82F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000029/0001551152-25-000029-index.htm.","url":"https://asof.is/claim/clm_E8E57D49C82F","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"136,165,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E8E57D49C82F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2025, filed 2025-05-09"}},{"date":"2025-04-30","until":"2025-07-29","published":"2025-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,766,403,027 shares\", as of 2025-04-30 (until 2025-07-29). Claim clm_4E3C69CACDA8, https://asof.is/claim/clm_4E3C69CACDA8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000029/0001551152-25-000029-index.htm.","url":"https://asof.is/claim/clm_4E3C69CACDA8","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,766,403,027 shares","status":"superseded","assertable":true,"id":"clm_4E3C69CACDA8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2025, filed 2025-05-09"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 6,467,000,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_6EBD1BCE1675, https://asof.is/claim/clm_6EBD1BCE1675, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000040/0001551152-25-000040-index.htm.","url":"https://asof.is/claim/clm_6EBD1BCE1675","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"6,467,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6EBD1BCE1675","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2025, filed 2025-08-04"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 15,423,000,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_83F895DA4455, https://asof.is/claim/clm_83F895DA4455, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000040/0001551152-25-000040-index.htm.","url":"https://asof.is/claim/clm_83F895DA4455","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"15,423,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_83F895DA4455","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2025, filed 2025-08-04"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 4,894,000,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_BA8EDB44AFDD, https://asof.is/claim/clm_BA8EDB44AFDD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000040/0001551152-25-000040-index.htm.","url":"https://asof.is/claim/clm_BA8EDB44AFDD","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"4,894,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BA8EDB44AFDD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2025, filed 2025-08-04"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: -183,000,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_BAE788922C38, https://asof.is/claim/clm_BAE788922C38, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000040/0001551152-25-000040-index.htm.","url":"https://asof.is/claim/clm_BAE788922C38","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"-183,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BAE788922C38","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2025, filed 2025-08-04"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 938,000,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_BC27B55DAB48, https://asof.is/claim/clm_BC27B55DAB48, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000040/0001551152-25-000040-index.htm.","url":"https://asof.is/claim/clm_BC27B55DAB48","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"938,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BC27B55DAB48","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2025, filed 2025-08-04"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 137,182,000,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_E991D9CEB134, https://asof.is/claim/clm_E991D9CEB134, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000040/0001551152-25-000040-index.htm.","url":"https://asof.is/claim/clm_E991D9CEB134","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"137,182,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E991D9CEB134","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2025, filed 2025-08-04"}},{"date":"2025-07-29","until":"2025-10-27","published":"2025-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,766,558,253 shares\", as of 2025-07-29 (until 2025-10-27). Claim clm_AAA173651D55, https://asof.is/claim/clm_AAA173651D55, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000040/0001551152-25-000040-index.htm.","url":"https://asof.is/claim/clm_AAA173651D55","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,766,558,253 shares","status":"superseded","assertable":true,"id":"clm_AAA173651D55","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2025, filed 2025-08-04"}},{"date":"2025-09-30","until":"2026-03-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 186,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_48C26099DBC0, https://asof.is/claim/clm_48C26099DBC0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_48C26099DBC0","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"186,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_48C26099DBC0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-04"}},{"date":"2025-09-30","until":"2026-03-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 15,776,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_7673BF825A9D, https://asof.is/claim/clm_7673BF825A9D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_7673BF825A9D","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"15,776,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7673BF825A9D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2025, filed 2025-11-04"}},{"date":"2025-09-30","until":"2026-03-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 1,904,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_8A7602897846, https://asof.is/claim/clm_8A7602897846, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_8A7602897846","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"1,904,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8A7602897846","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-04"}},{"date":"2025-09-30","until":"2025-12-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 133,898,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_9AD5C074902A, https://asof.is/claim/clm_9AD5C074902A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_9AD5C074902A","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"133,898,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9AD5C074902A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2025, filed 2025-11-04"}},{"date":"2025-09-30","until":"2025-12-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 5,629,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_E498EA77B417, https://asof.is/claim/clm_E498EA77B417, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_E498EA77B417","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"5,629,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E498EA77B417","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2025, filed 2025-11-04"}},{"date":"2025-09-30","until":"2025-12-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: -2,642,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_E6BEEAB8A7CC, https://asof.is/claim/clm_E6BEEAB8A7CC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_E6BEEAB8A7CC","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"-2,642,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E6BEEAB8A7CC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2025, filed 2025-11-04"}},{"date":"2025-10-27","until":"2026-02-10","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,767,384,632 shares\", as of 2025-10-27 (until 2026-02-10). Claim clm_A66CE3EA88E8, https://asof.is/claim/clm_A66CE3EA88E8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_A66CE3EA88E8","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,767,384,632 shares","status":"superseded","assertable":true,"id":"clm_A66CE3EA88E8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2025, filed 2025-11-04"}},{"date":"2025-12-31","until":null,"published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie net income: 4,226,000,000 United States dollar\", as of 2025-12-31. Claim clm_2A3E6A20A337, https://asof.is/claim/clm_2A3E6A20A337, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/0001551152-26-000008-index.htm.","url":"https://asof.is/claim/clm_2A3E6A20A337","accessed":"2026-11-09"},"kind":"money","predicate":"net_income","value":"4,226,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_2A3E6A20A337","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2025, filed 2026-02-20"}},{"date":"2025-12-31","until":null,"published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie revenue: 61,160,000,000 United States dollar\", as of 2025-12-31. Claim clm_4A7BE8ED0078, https://asof.is/claim/clm_4A7BE8ED0078, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/0001551152-26-000008-index.htm.","url":"https://asof.is/claim/clm_4A7BE8ED0078","accessed":"2026-11-09"},"kind":"money","predicate":"revenue","value":"61,160,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_4A7BE8ED0078","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2025, filed 2026-02-20"}},{"date":"2025-12-31","until":"2026-03-31","published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: -3,270,000,000 United States dollar\", as of 2025-12-31 (until 2026-03-31). Claim clm_6A970AB08DB3, https://asof.is/claim/clm_6A970AB08DB3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/0001551152-26-000008-index.htm.","url":"https://asof.is/claim/clm_6A970AB08DB3","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"-3,270,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6A970AB08DB3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2025, filed 2026-02-20"}},{"date":"2025-12-31","until":"2026-03-31","published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 133,960,000,000 United States dollar\", as of 2025-12-31 (until 2026-03-31). Claim clm_BAF68C4E73F9, https://asof.is/claim/clm_BAF68C4E73F9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/0001551152-26-000008-index.htm.","url":"https://asof.is/claim/clm_BAF68C4E73F9","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"133,960,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BAF68C4E73F9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2025, filed 2026-02-20"}},{"date":"2025-12-31","until":null,"published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie operating income: 15,075,000,000 United States dollar\", as of 2025-12-31. Claim clm_D4AF640165D7, https://asof.is/claim/clm_D4AF640165D7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/0001551152-26-000008-index.htm.","url":"https://asof.is/claim/clm_D4AF640165D7","accessed":"2026-11-09"},"kind":"money","predicate":"operating_income","value":"15,075,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_D4AF640165D7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2025, filed 2026-02-20"}},{"date":"2025-12-31","until":"2026-03-31","published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 5,229,000,000 United States dollar\", as of 2025-12-31 (until 2026-03-31). Claim clm_F526599F9FFE, https://asof.is/claim/clm_F526599F9FFE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/0001551152-26-000008-index.htm.","url":"https://asof.is/claim/clm_F526599F9FFE","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"5,229,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F526599F9FFE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2025, filed 2026-02-20"}},{"date":"2026-02-10","until":"2026-04-28","published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,768,169,012 shares\", as of 2026-02-10 (until 2026-04-28). Claim clm_F33386E6A71F, https://asof.is/claim/clm_F33386E6A71F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/0001551152-26-000008-index.htm.","url":"https://asof.is/claim/clm_F33386E6A71F","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,768,169,012 shares","status":"superseded","assertable":true,"id":"clm_F33386E6A71F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2025, filed 2026-02-20"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 15,002,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_2A1D46B6132E, https://asof.is/claim/clm_2A1D46B6132E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000017/0001551152-26-000017-index.htm.","url":"https://asof.is/claim/clm_2A1D46B6132E","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"15,002,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2A1D46B6132E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2026, filed 2026-05-08"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 3,990,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_78F42A193166, https://asof.is/claim/clm_78F42A193166, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000017/0001551152-26-000017-index.htm.","url":"https://asof.is/claim/clm_78F42A193166","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"3,990,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_78F42A193166","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2026, filed 2026-05-08"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: -6,656,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_86F602E30464, https://asof.is/claim/clm_86F602E30464, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000017/0001551152-26-000017-index.htm.","url":"https://asof.is/claim/clm_86F602E30464","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"-6,656,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_86F602E30464","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2026, filed 2026-05-08"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 695,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_879DEDC1ACEA, https://asof.is/claim/clm_879DEDC1ACEA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000017/0001551152-26-000017-index.htm.","url":"https://asof.is/claim/clm_879DEDC1ACEA","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"695,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_879DEDC1ACEA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2026, filed 2026-05-08"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 136,463,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_CD090548C18D, https://asof.is/claim/clm_CD090548C18D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000017/0001551152-26-000017-index.htm.","url":"https://asof.is/claim/clm_CD090548C18D","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"136,463,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CD090548C18D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2026, filed 2026-05-08"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 9,391,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_E7E1876E4E88, https://asof.is/claim/clm_E7E1876E4E88, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000017/0001551152-26-000017-index.htm.","url":"https://asof.is/claim/clm_E7E1876E4E88","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"9,391,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E7E1876E4E88","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2026, filed 2026-05-08"}},{"date":"2026-04-28","until":"2026-07-27","published":"2026-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,766,792,821 shares\", as of 2026-04-28 (until 2026-07-27). Claim clm_7C1384CB0CC0, https://asof.is/claim/clm_7C1384CB0CC0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000017/0001551152-26-000017-index.htm.","url":"https://asof.is/claim/clm_7C1384CB0CC0","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,766,792,821 shares","status":"superseded","assertable":true,"id":"clm_7C1384CB0CC0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2026, filed 2026-05-08"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: -5,935,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_00E837EDC859, https://asof.is/claim/clm_00E837EDC859, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/0001551152-26-000026-index.htm.","url":"https://asof.is/claim/clm_00E837EDC859","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"-5,935,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_00E837EDC859","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2026, filed 2026-08-03"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 6,569,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_2B61F63D78FE, https://asof.is/claim/clm_2B61F63D78FE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/0001551152-26-000026-index.htm.","url":"https://asof.is/claim/clm_2B61F63D78FE","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"6,569,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2B61F63D78FE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2026, filed 2026-08-03"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 6,432,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_67BFBB091A03, https://asof.is/claim/clm_67BFBB091A03, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/0001551152-26-000026-index.htm.","url":"https://asof.is/claim/clm_67BFBB091A03","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"6,432,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_67BFBB091A03","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2026, filed 2026-08-03"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 3,613,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_A0327C4F8772, https://asof.is/claim/clm_A0327C4F8772, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/0001551152-26-000026-index.htm.","url":"https://asof.is/claim/clm_A0327C4F8772","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"3,613,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A0327C4F8772","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2026, filed 2026-08-03"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 135,115,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_A320A5717609, https://asof.is/claim/clm_A320A5717609, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/0001551152-26-000026-index.htm.","url":"https://asof.is/claim/clm_A320A5717609","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"135,115,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A320A5717609","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2026, filed 2026-08-03"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 16,990,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_E6270C8DB4ED, https://asof.is/claim/clm_E6270C8DB4ED, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/0001551152-26-000026-index.htm.","url":"https://asof.is/claim/clm_E6270C8DB4ED","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"16,990,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E6270C8DB4ED","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2026, filed 2026-08-03"}},{"date":"2026-07-27","until":"2026-10-26","published":"2026-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,767,117,285 shares\", as of 2026-07-27 (until 2026-10-26). Claim clm_86C65743AE05, https://asof.is/claim/clm_86C65743AE05, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/0001551152-26-000026-index.htm.","url":"https://asof.is/claim/clm_86C65743AE05","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,767,117,285 shares","status":"superseded","assertable":true,"id":"clm_86C65743AE05","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2026, filed 2026-08-03"}},{"date":"2026-09-30","until":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 147,680,000,000 United States dollar\", as of 2026-09-30. Claim clm_0DE2793ECF77, https://asof.is/claim/clm_0DE2793ECF77, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm.","url":"https://asof.is/claim/clm_0DE2793ECF77","accessed":"2026-11-09"},"kind":"money","predicate":"total_assets","value":"147,680,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_0DE2793ECF77","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2026, filed 2026-11-03"}},{"date":"2026-09-30","until":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 6,267,000,000 United States dollar\", as of 2026-09-30. Claim clm_5AF8A08D6F94, https://asof.is/claim/clm_5AF8A08D6F94, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm.","url":"https://asof.is/claim/clm_5AF8A08D6F94","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_operating_income","value":"6,267,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_5AF8A08D6F94","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2026, filed 2026-11-03"}},{"date":"2026-09-30","until":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 10,774,000,000 United States dollar\", as of 2026-09-30. Claim clm_A17F69D94691, https://asof.is/claim/clm_A17F69D94691, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm.","url":"https://asof.is/claim/clm_A17F69D94691","accessed":"2026-11-09"},"kind":"money","predicate":"cash_and_equivalents","value":"10,774,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_A17F69D94691","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2026, filed 2026-11-03"}},{"date":"2026-09-30","until":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 4,218,000,000 United States dollar\", as of 2026-09-30. Claim clm_B8246C4E0E64, https://asof.is/claim/clm_B8246C4E0E64, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm.","url":"https://asof.is/claim/clm_B8246C4E0E64","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_net_income","value":"4,218,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_B8246C4E0E64","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2026, filed 2026-11-03"}},{"date":"2026-09-30","until":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 17,404,000,000 United States dollar\", as of 2026-09-30. Claim clm_DA52AAE1BFB4, https://asof.is/claim/clm_DA52AAE1BFB4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm.","url":"https://asof.is/claim/clm_DA52AAE1BFB4","accessed":"2026-11-09"},"kind":"money","predicate":"quarterly_revenue","value":"17,404,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_DA52AAE1BFB4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2026, filed 2026-11-03"}},{"date":"2026-09-30","until":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: -4,583,000,000 United States dollar\", as of 2026-09-30. Claim clm_FA883B408C6E, https://asof.is/claim/clm_FA883B408C6E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm.","url":"https://asof.is/claim/clm_FA883B408C6E","accessed":"2026-11-09"},"kind":"money","predicate":"total_equity","value":"-4,583,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_FA883B408C6E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2026, filed 2026-11-03"}},{"date":"2026-10-26","until":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,767,616,306 shares\", as of 2026-10-26. Claim clm_54135339A00E, https://asof.is/claim/clm_54135339A00E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm.","url":"https://asof.is/claim/clm_54135339A00E","accessed":"2026-11-09"},"kind":"money","predicate":"shares_outstanding","value":"1,767,616,306 shares","status":"valid","assertable":true,"id":"clm_54135339A00E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2026, filed 2026-11-03"}}],"complete":true,"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing"}}}